

MEDICIS PHARMACEUTICAL CORP

Form 10-Q

May 10, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 10-Q**

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934**

For the quarterly period ended March 31, 2005

OR

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-18443

**MEDICIS PHARMACEUTICAL CORPORATION**

---

(Exact name of Registrant as specified in its charter)

Delaware

52-1574808

(State or other jurisdiction of  
incorporation or organization)

(I.R.S. Employer Identification No.)

8125 North Hayden Road  
Scottsdale, Arizona 85258-2463

(Address of principal executive offices)  
(602) 808-8800

(Registrant's telephone number,  
including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2) YES  NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class  
Class A Common Stock \$.014 Par Value

Outstanding at May 5, 2005  
54,263,826

---

**MEDICIS PHARMACEUTICAL CORPORATION**

**Table of Contents**

	Page
<b><u>PART</u></b>	
<b><u>I.</u></b>	
<b><u>FINANCIAL INFORMATION</u></b>	
<b><u>Item 1 Financial Statements</u></b>	
<u>Condensed Consolidated Balance Sheets as of March 31, 2005 and June 30, 2004</u>	3
<u>Condensed Consolidated Statements of Income for the Three and Nine Months Ended March 31, 2005 and 2004</u>	5
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2005 and 2004</u>	6
<u>Notes to the Condensed Consolidated Financial Statements</u>	7
<b><u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	18
<b><u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u></b>	37
<b><u>Item 4 Controls and Procedures</u></b>	37
<b><u>PART</u></b>	
<b><u>II.</u></b>	
<b><u>OTHER INFORMATION</u></b>	
<u>Item 1 Legal Proceedings</u>	38
<u>Item 2 Unregistered Sales of Securities and Use of Proceeds</u>	40
<u>Item 6 Exhibits</u>	41
<b><u>SIGNATURES</u></b>	42
<u>EX-4.1</u>	
<u>EX-12</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	

**Table of Contents****Part I. Financial Information****Item 1. Financial Statements****MEDICIS PHARMACEUTICAL CORPORATION****CONDENSED CONSOLIDATED BALANCE SHEETS****(in thousands, except share amounts)**

	March 31, 2005 (unaudited)	June 30, 2004
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 68,173	\$ 46,621
Short-term investments	493,081	587,419
Accounts receivable, net	48,004	47,858
Inventories, net	19,067	19,540
Deferred tax assets, net	15,642	14,104
Other current assets	15,560	18,321
Total current assets	659,527	733,863
Property and equipment, net	6,346	5,842
Intangible assets:		
Intangible assets related to product line acquisitions and business combinations	314,650	312,416
Other intangible assets	16,077	15,288
	330,727	327,704
Less: accumulated amortization	66,365	51,961
Net intangible assets	264,362	275,743
Goodwill	65,135	55,401
Deferred financing costs, net	5,933	7,535
Other non-current assets	7,096	
	\$ 1,008,399	\$ 1,078,384

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except share amounts)

	March 31, 2005 (unaudited)	June 30, 2004
<b>Liabilities</b>		
Current liabilities:		
Accounts payable	\$ 28,954	\$ 13,912
Short-term contract obligation	27,491	17,891
Income taxes payable	4,759	712
Other current liabilities	27,624	34,605
Total current liabilities	88,828	67,120
Long-term liabilities:		
Contingent convertible senior notes	453,065	453,067
Deferred tax liability, net	4,890	2,894
<b>Stockholders Equity</b>		
Preferred stock, \$0.01 par value; shares authorized: 5,000,000; no shares issued		
Class A common stock, \$0.014 par value; shares authorized: 150,000,000; issued and outstanding: 66,968,400 and 65,419,460 at March 31, 2005 and June 30, 2004, respectively	937	916
Class B common stock, \$0.014 par value; shares authorized: 1,000,000; issued and outstanding: 0 and 758,032 at March 31, 2005 and June 30, 2004, respectively		10
Additional paid-in capital	537,867	517,468
Accumulated other comprehensive income	(1,163)	(1,020)
Deferred compensation	(825)	(1,212)
Accumulated earnings	265,708	230,049
Less: Treasury stock, 12,602,554 and 8,681,468 shares at cost at March 31, 2005 and at June 30, 2004, respectively	(340,908)	(190,908)
Total stockholders equity	461,616	555,303
	\$ 1,008,399	\$ 1,078,384

See accompanying notes to condensed consolidated financial statements.

Table of Contents**MEDICIS PHARMACEUTICAL CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
**(unaudited)****(in thousands, except per share data)**

	Three Months Ended		Nine Months Ended	
	March 31,		March 31,	
	2005	2004	2005	2004
Net product revenues	\$ 75,788	\$ 80,974	\$ 222,787	\$ 211,572
Net contract revenues	19,400	865	53,568	4,195
Net revenues	95,188	81,839	276,355	215,767
Cost of product revenue (1)	13,914	13,118	41,185	34,536
Gross profit	81,274	68,721	235,170	181,231
Operating costs and expenses:				
Selling, general and administrative	31,934	28,793	97,670	87,907
Research and development	14,452	3,084	59,591	12,375
Depreciation and amortization	6,054	4,707	16,276	11,872
Operating costs and expenses	52,440	36,584	173,537	112,154
Operating income	28,834	32,137	61,633	69,077
Interest income	2,989	2,309	8,065	7,714
Interest expense	(2,658)	(2,644)	(7,982)	(8,163)
Loss on early extinguishment of debt				(58,660)
Income before income tax expense	29,165	31,802	61,716	9,968
Income tax expense	(9,794)	(11,131)	(21,121)	(2,833)
Net income	\$ 19,371	\$ 20,671	\$ 40,595	\$ 7,135
Basic net income per share	\$ 0.36	\$ 0.37	\$ 0.73	\$ 0.13

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Diluted net income per share	\$ 0.30	\$ 0.31	\$ 0.64	\$ 0.12
Cash dividend declared per common share	\$ 0.03	\$ 0.025	\$ 0.09	\$ 0.075
Basic common shares outstanding	54,251	56,042	55,506	55,198
Diluted common shares outstanding	69,773	73,164	71,489	58,569

---

(1) amounts exclude amortization of intangible assets related to acquired products as follows:	\$ 5,342	\$ 4,165	\$ 14,274	\$ 10,558
---	----------	----------	-----------	-----------

See accompanying notes to condensed consolidated financial statements.

**Table of Contents****MEDICIS PHARMACEUTICAL CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(unaudited)****(in thousands)**

	Nine Months Ended	
	March 31, 2005	March 31, 2004
<b>Operating Activities:</b>		
Net income	\$ 40,595	\$ 7,135
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	17,884	13,491
Loss on disposal of property and equipment	36	
Loss (gain) on sale of available-for-sale investments	259	(396)
Amortization of deferred compensation	386	386
Deferred income tax expense (benefit)	458	(3,732)
Tax benefit from exercise of stock options	4,605	15,268
Provision for doubtful accounts and returns	3,100	1,250
Accretion of premium on investments	6,409	4,787
Loss on early extinguishment of debt		58,660
Changes in operating assets and liabilities:		
Accounts receivable	(3,246)	509
Inventories	474	(5,603)
Other current assets	2,761	(10,871)
Accounts payable	8,761	(4,704)
Income taxes payable	4,046	(422)
Other current liabilities	(7,174)	1,670
Net cash provided by operating activities	79,354	77,428
<b>Investing Activities:</b>		
Purchase of property and equipment	(2,411)	(3,658)
Payment of direct merger costs	(949)	(547)
Payments for purchase of product rights	(3,023)	(59,487)
Purchase of available-for-sale investments	(626,072)	(673,691)
Sale of available-for-sale investments	660,935	503,826
Maturity of available-for-sale investments	51,876	92,874
Decrease in restricted cash		53,837
Change in other assets		8
Net cash provided by (used in) investing activities	80,356	(86,838)
<b>Financing Activities:</b>		
Payment of deferred financing costs	(7)	(5,041)
Payment of dividends	(4,742)	(4,117)



Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Purchase of treasury stock	(150,000)	
Proceeds from the exercise of stock options	15,803	37,032
Net cash (used in) provided by financing activities	(138,946)	27,874
Effect of exchange rate on cash and cash equivalents	788	286
Net increase in cash and cash equivalents	21,552	18,750
Cash and cash equivalents at beginning of period	46,621	44,346
Cash and cash equivalents at end of period	\$ 68,173	\$ 63,096

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**March 31, 2005  
(unaudited)**

**1. NATURE OF BUSINESS**

Medicis Pharmaceutical Corporation is a leading specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing of products in the United States for the treatment of dermatological, aesthetic and podiatric conditions. Medicis also markets products in Canada for the treatment of dermatological and aesthetic conditions. Medicis has built its business by executing a four-part growth strategy. This strategy consists of promoting existing core brands, developing new products and important product line extensions, entering into strategic collaborations, and acquiring complementary products, technologies and businesses.

The Company offers a broad range of products addressing various conditions including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis currently offers 15 branded products. Its core brands are DYNACIN<sup>®</sup> (minocycline HCl), LOPROX<sup>®</sup> (ciclopirox), OMNICEF<sup>®</sup> (cefдинир), PLEXION<sup>®</sup> (sodium sulfacetamide/sulfur), RESTYLANE<sup>®</sup> (hyaluronic acid), TRIAZ<sup>®</sup> (benzoyl peroxide), and VANOS (fluocinonide) Cream, 0.1%.

In March 2003, Medicis expanded into the dermal aesthetic market through its acquisition of the exclusive United States and Canadian rights to market, distribute and commercialize the dermal restorative product lines known as RESTYLANE<sup>®</sup>, PERLANE and RESTYLANE FINE LINES from Q-Med AB, a Swedish biotechnology/medical device company and its affiliates, collectively Q-Med. RESTYLANE<sup>®</sup> has been approved by the Food and Drug Administration (the FDA) for use in the United States as a medical device for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. RESTYLANE<sup>®</sup>, PERLANE and RESTYLANE FINE LINES have been approved for use in Canada.

The condensed consolidated financial statements include the accounts of Medicis Pharmaceutical Corporation and its wholly owned subsidiaries ( Medicis or the Company ). The Company does not have any subsidiaries in which it does not own 100% of the outstanding stock. All of the Company's subsidiaries are included in the condensed consolidated financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying interim condensed consolidated financial statements of Medicis have been prepared in conformity with U.S. generally accepted accounting principles, consistent in all material respects with those applied in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2004. The financial information is unaudited but reflects all adjustments, consisting only of normal recurring accruals, which are, in the opinion of the Company's management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with the Company's Annual Report on Form 10-K for fiscal 2004. Certain prior period amounts have been reclassified to conform with current period presentation.

**2. CHANGE IN ESTIMATE**

During the three months ended March 31, 2005, the Company changed the estimated useful life for certain intangible assets related to its merger with Ascent Pediatrics, Inc. ( Ascent ), based on management's determination that these intangible assets appear to have shorter useful lives than originally estimated. There is no cumulative effect for this change. The effect of this change on net income for the three months ended March 31, 2005 was to decrease net income by approximately \$540,000 or \$0.01 per diluted common share.

**Table of Contents****3. STOCK-BASED COMPENSATION**

At March 31, 2005, the Company had six stock-based employee compensation plans. The Company accounts for those plans under the recognition and measurement principles of Accounting Principles Board Opinion No. 25,

Accounting for Stock Issued to Employees and related Interpretations. Other than restricted stock, no stock-based employee compensation cost is reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (SFAS No. 123), to stock-based employee compensation (amounts in thousands, except per share amounts):

	<b>THREE MONTHS ENDED MARCH 31,</b>		<b>NINE MONTHS ENDED MARCH 31,</b>	
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Net income, as reported	\$ 19,371	\$ 20,671	\$ 40,595	\$ 7,135
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	5,049	4,674	15,244	13,771
Pro-forma net income (loss)	\$ 14,322	\$ 15,997	\$ 25,351	\$ (6,636)
Earnings per share:				
Basic as reported	\$ 0.36	\$ 0.37	\$ 0.73	\$ 0.13
Basic pro forma	\$ 0.26	\$ 0.29	\$ 0.46	\$ (0.12)
Diluted as reported	\$ 0.30	\$ 0.31	\$ 0.64	\$ 0.12
Diluted pro forma	\$ 0.23	\$ 0.24	\$ 0.42	\$ (0.12)

As required, the pro forma disclosures above include options granted since April 1, 1996. Consequently, the effects of applying SFAS No. 123 for providing pro forma disclosures may not be representative of the effects on reported net income for future years until all options outstanding are included in the pro forma disclosures. For purposes of pro forma disclosures, the estimated fair value of stock-based compensation plans and other options is amortized to expense primarily over the vesting period.

On December 16, 2004, the FASB issued Statement No. 123R, Share-Based Payment (SFAS No. 123R), which requires companies to measure and recognize compensation expense for all stock-based payments at fair value. Stock-based payments include stock option grants. The Company grants options to purchase common stock to some of its employees and directors under various plans at prices equal to the market value of the stock on the dates the options were granted. The Company is required to adopt SFAS No. 123R in its first quarter of fiscal 2006, beginning July 1, 2005. The Company has not yet adopted this pronouncement and is currently evaluating the expected impact that the adoption of SFAS No. 123R will have on its consolidated financial position, results of operations and cash flows; however, SFAS No. 123R will negatively impact the Company's earnings.

**4. RESEARCH AND DEVELOPMENT COSTS AND ACCOUNTING FOR STRATEGIC COLLABORATIONS**

All research and development costs, including payments related to products under development, and research consulting agreements, are expensed as incurred. The Company makes up-front, non-refundable payments to third parties for new technologies and for research and development work that has been completed. These up-front payments may be expensed at the time of payment depending on the nature of the payment made.

**Table of Contents**

The Company's policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization.

On January 28, 2005, the Company amended its strategic alliance with aaiPharma Inc. ( aaiPharma ) previously initiated in June 2002 for the development, commercialization and license of a dermatologic product. The consummation of the amendment has not affected the timing of the development project. The amendment allowed for the immediate transfer of the work product as defined under the agreement, as well as the product's management and development, to Medicis, and provides that aaiPharma will continue to assist Medicis with the development of the product on a fee for services basis. Medicis will have no future financial obligations to pay aaiPharma on the attainment of clinical milestones, but incurred approximately \$8.3 million as a charge to research and development expense during the three months ended March 31, 2005, as part of the amendment and the assumption of all liabilities associated with the project.

In addition to the amendment, Medicis entered into a supply agreement with aaiPharma for the eventual manufacture of the product by aaiPharma under certain conditions. Medicis has the right to qualify an alternate manufacturing facility, and aaiPharma agreed to assist Medicis in obtaining these qualifications. Upon the approval of the alternate facility and approval of the product, Medicis will pay aaiPharma approximately \$1 million.

On December 13, 2004, the Company entered into an exclusive development and license agreement and other ancillary agreements with Ansata Therapeutics, Inc. ( Ansata ). The development and license agreement grants Medicis the exclusive, worldwide rights to Ansata's early stage, proprietary antimicrobial peptide technology. In accordance with the development and license agreement, Medicis paid \$5 million upon signing of the contract and will pay approximately \$9 million upon the successful completion of certain developmental milestones. Should Medicis continue with the development of this technology, the Company will incur additional milestone payments beyond the development and license agreement. The initial \$5 million payment was recorded as a charge to research and development expense during the second quarter of fiscal 2005. The Company also incurred approximately \$0.5 million of professional fees related to the completion of the agreements, which was included in selling, general and administrative expenses during the second quarter of fiscal 2005. In addition, the Company entered into an Option Agreement with Ansata where Medicis has the option to acquire Ansata or certain assets of Ansata if certain financial conditions are present.

On April 19, 1999, the Company acquired 100% of the common stock of Ucyclid Pharma, Inc. ( Ucyclid ), a privately held pharmaceutical company based in Baltimore, Maryland, for net cash of approximately \$14.3 million. Ucyclid's primary products, BUPHENY<sup>®</sup> and AMMONUL<sup>®</sup>, are indicated in the treatment of Urea Cycle Disorder. Under terms of the agreement, the Company paid \$15.1 million on April 19, 1999, and paid an additional \$5.7 million in contingent payments in April 2000. In November 2004, the Company paid \$2.7 million to the former shareholders of Ucyclid as the final contractual purchase price payment. This \$2.7 million payment was recorded as an addition to the original Ucyclid intangible asset in the Company's condensed consolidated balance sheets.

On July 15, 2004, the Company entered into an exclusive license agreement and other ancillary documents with Q-Med to market, distribute, sell and commercialize in the United States and Canada Q-Med's product currently known as SubQ<sup>™</sup>. Q-Med has the exclusive right to manufacture SubQ<sup>™</sup> for Medicis. SubQ<sup>™</sup> is currently not approved for use in the United States or Canada. Under terms of the license agreement, Medicis Aesthetics Holdings Inc., a wholly owned subsidiary of Medicis, licenses SubQ<sup>™</sup> for approximately \$80 million, due as follows: approximately \$30 million on July 15, 2004, which was recorded as a charge to research and development expense during the first quarter of fiscal 2005; approximately \$10 million upon completion of certain clinical milestones; approximately \$20 million upon satisfaction of certain defined regulatory milestones; and approximately \$20 million

upon U.S. launch of SubQ™. In addition, the Company incurred approximately \$0.7 million of professional fees related to the completion of the agreements during the first quarter of fiscal 2005, which was included in selling, general

**Table of Contents**

and administrative expenses. The Company also will make additional milestone payments to Q-Med upon the achievement of certain commercial milestones.

**5. DEFINITIVE MERGER AGREEMENT WITH INAMED CORPORATION**

On March 20, 2005, Medicis, a wholly-owned subsidiary of Medicis and Inamed Corporation ( Inamed ) entered into an Agreement and Plan of Merger. Inamed is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND® system for morbid obesity.

Under the terms of the Agreement and Plan of Merger, Inamed will merge with and into a subsidiary of Medicis and each share of Inamed common stock will be converted into the right to receive 1.4205 shares of Medicis common stock and \$30.00 in cash. The completion of the transaction is subject to several customary conditions, including the receipt of applicable approvals from Medicis and Inamed's stockholders, the absence of any material adverse effect on either party's business and the receipt of regulatory approvals. It is currently anticipated that the closing of the transaction would occur by the end of calendar 2005.

During the third quarter of fiscal 2005, the Company incurred approximately \$7.1 million of professional and other costs related to the transaction. The costs are included in other non-current assets in the accompanying condensed consolidated balance sheets. The discussions in this report relate to Medicis as a stand-alone entity and do not reflect the impact of the proposed merger with Inamed.

The Agreement and Plan of Merger was filed with the SEC by the Company as part of an 8-K filed on March 21, 2005.

**6. LICENSE OF ORAPRED® TO BIOMARIN**

On May 18, 2004, the Company closed an asset purchase agreement and license agreement and executed a securities purchase agreement with BioMarin. The asset purchase agreement involves BioMarin's purchase of assets related to ORAPRED®, including assets concerning the Ascent field sales force. ORAPRED® and related pediatric intellectual property is owned by Ascent, a wholly owned subsidiary of Medicis. The license agreement granted BioMarin, among other things, the exclusive worldwide rights to ORAPRED®. The securities purchase agreement granted BioMarin the option to purchase all outstanding shares of common stock of Ascent, based on certain conditions. As part of the transaction, the name of Ascent Pediatrics, Inc. was changed to Medicis Pediatrics, Inc.

Under terms of the agreements, BioMarin was to make license payments to Ascent of approximately \$93 million payable over a five-year period as follows: approximately \$10 million as of the date of the transaction; approximately \$12.5 million per quarter for four quarters beginning in July 2004; approximately \$2.5 million per quarter for the subsequent four quarters beginning in July 2005; approximately \$2 million per quarter for the subsequent eight quarters beginning in July 2006; and approximately \$1.75 million per quarter for the last four quarters of the five-year period beginning in July 2008. BioMarin was also to make payments of \$2.5 million per quarter for six quarters beginning in July 2004 for reimbursement of certain contingent payments as discussed in Note 8. As of March 31, 2005, BioMarin had paid \$55.0 million to Medicis under the license agreement, which represents all scheduled payments due through that date under the license agreement. The license agreement will terminate in July 2009. At that time, based on certain conditions, BioMarin would have the option to purchase all outstanding shares of Ascent for approximately \$82 million. The payment was to consist of \$62 million in cash and \$20 million in BioMarin common stock, based on the fair value of the stock at that time. The Company is responsible for the manufacture and delivery of finished goods inventory to BioMarin, and BioMarin is responsible for paying the Company for future finished goods inventory delivered through June 30, 2005. As a result, the Company is required to recognize the first



\$60 million of license payments ratably through June 30, 2005. The Company has deferred approximately \$0.9 million and \$3.5 million in revenue under the agreement as of March 31, 2005, and June 30, 2004, respectively. The license payments

**Table of Contents**

received after June 30, 2005 and the reimbursement of contingent payments will be recognized as revenue when all four criteria of SAB 104 have been met.

As of the closing date of the transaction, BioMarin is responsible for all marketing and promotional efforts regarding the sale of ORAPRED®. As a result, Medicis no longer advertises and promotes any oral liquid prednisolone sodium phosphate solution product or any related line extension. During the term of the license agreement, Medicis will maintain ownership of the intellectual property and, consequently, will continue to amortize the related intangible assets. Payments received from BioMarin under the license agreement will be treated as contract revenue, which is included in net revenues in the condensed consolidated statements of income.

On January 12, 2005, BioMarin and the Company entered into amendments to the Securities Purchase Agreement and License Agreement entered into on May 18, 2004, a Convertible Promissory Note ( Convertible Note ) and a Settlement and Mutual Release Agreement (collectively the Agreements ). Under the terms of the Agreements, transaction payments from BioMarin to Medicis previously totaling \$175 million were reduced to \$159 million. Beginning with license payments relating to ORAPRED® to be made by BioMarin after July 2005, license payments totaling \$93 million were reduced pro rata to \$88.4 million. Consideration to be received by Medicis from BioMarin in 2009 for the option relating to the purchase of all outstanding shares of Ascent Pediatrics were reduced from \$82 million to \$70.6 million. Medicis will take full financial responsibility for contingent payments due to former Ascent Pediatric shareholders without the \$5 million offset payment that would have been paid by BioMarin to Medicis after July 1, 2005. Contingent payments are due to former Ascent Pediatric shareholders from Medicis only if revenue from Ascent Pediatric products exceeds certain thresholds. In addition, Medicis will reimburse BioMarin for actual returns, up to certain agreed-upon limits, of ORAPRED® finished goods received by BioMarin during the quarters ended December 31, 2004, March 31, 2005 and June 30, 2005.

Additionally, Medicis will make available to BioMarin a Convertible Note up to \$25 million beginning July 1, 2005 based on certain terms and conditions including a change of control provision. Money advanced under the Convertible Note is convertible into BioMarin shares at a strike price equal to the BioMarin average closing price for the 20 trading days prior to such advance. The Convertible Note matures on the option purchase date in 2009 as defined in the Securities Purchase Agreement but may be repaid by BioMarin at any time prior to the option purchase date. In conjunction with the Agreements, BioMarin and Medicis have entered into a settlement and Mutual Release Agreement to forever discharge each other from any and all claims, demands, damages, debts, liabilities, actions and causes of action relating to the transaction consummated by the parties other than certain continuing obligations in accordance with the terms of the parties agreements.

**7. ACQUISITION OF DERMAL AESTHETIC ENHANCEMENT PRODUCTS FROM THE Q-MED GROUP**

On March 10, 2003, Medicis acquired all outstanding shares of HA North American Sales AB from Q-Med, a Swedish biotechnology/medical device company. HA North American Sales AB holds a license for the exclusive U.S. and Canadian rights to market, distribute and commercialize the dermal restorative product lines known as RESTYLANE®, PERLANE and RESTYLANE FINE LINES. RESTYLANE® has been approved by the FDA for use in the United States. RESTYLANE®, PERLANE and RESTYLANE FINE LINES have been approved for use in Canada. Under terms of the agreements, a wholly owned subsidiary of Medicis acquired all outstanding shares of HA North American Sales AB for total consideration of approximately \$160.0 million, payable upon the successful completion of certain milestones or events. Medicis paid \$58.2 million upon closing of the transaction, \$53.3 million in December 2003 upon FDA approval of RESTYLANE®, approximately \$19.4 million in May 2004 upon certain cumulative commercial milestones being achieved and will pay approximately \$29.1 million upon FDA approval of PERLANE. Payments and costs related to this acquisition are capitalized as an intangible asset and are amortized over 15 years beginning in March 2003.



**Table of Contents****8. MERGER OF ASCENT PEDIATRICS, INC.**

As part of its merger with Ascent completed in November 2001, the Company may be required to make contingent purchase price payments ( Contingent Payments ) for each of the first five years following closing based upon reaching certain sales threshold milestones on the Ascent products for each twelve month period ended November 15, 2006, subject to certain deductions and set-offs. From time to time the Company assesses the probability and likelihood of payment in the coming respective November period based on current sales trends. There can be no assurance that such payment will ultimately be made nor is the accrual of a liability an indication of current sales levels. During the quarter ended December 31, 2004, the threshold for the third year Contingent Payment was met, and approximately \$9.6 million was recorded as an increase to goodwill and short-term contract obligation. A total of approximately \$27.5 million is included in short-term contract obligation in the Company s condensed consolidated balance sheets as of March 31, 2005, representing the first three years Contingent Payments. Pursuant to the merger agreement, payment of the contingent portion of the purchase price will be withheld pending the final outcome of the litigation discussed in Part II of this Form 10-Q.

**9. SEGMENT AND PRODUCT INFORMATION**

The Company operates in one significant business segment: Pharmaceuticals. The Company s current pharmaceutical franchises are divided between the Dermatological and Non-dermatological fields. The Dermatological field represents products for the treatment of Acne and Acne-related dermatological conditions and Non-acne dermatological conditions. The Non-dermatological field represents products for the treatment of Asthma (until May 2004) and Urea Cycle Disorder. The Acne and Acne-related dermatological product lines include core brands DYNACIN<sup>®</sup>, PLEXION<sup>®</sup> and TRIAZ<sup>®</sup>. The Non-acne dermatological product lines include core brands LOPROX<sup>®</sup>, OMNICEF<sup>®</sup>, RESTYLANE<sup>®</sup> and VANOS. The Non-dermatological product lines include AMMONUL<sup>®</sup>, BUPHENYL<sup>®</sup> and ORAPRED<sup>®</sup>. ORAPRED<sup>®</sup> was one of the Company s core brands until it was licensed to BioMarin in May 2004. The Non-dermatological field also includes contract revenues associated with licensing agreements and authorized generics.

The Company s pharmaceutical products, with the exception of AMMONU<sup>®</sup> and BUPHENYL<sup>®</sup>, are promoted to dermatologists, podiatrists and plastic surgeons. Such products are often prescribed by physicians outside these three specialties; including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies and others. All products, with the exception of AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, are sold primarily to wholesalers and retail chain drug stores. AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup> are primarily sold directly to hospitals and pharmacies. Prior to the Company s licensing of ORAPRED<sup>®</sup> to BioMarin in May 2004, the Company also promoted its pharmaceutical products to pediatricians.

The percentage of net revenues for each of the product categories is as follows:

	<b>THREE MONTHS ENDED MARCH 31,</b>		<b>NINE MONTHS ENDED MARCH 31,</b>	
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Acne and acne-related dermatological products	25%	25%	30%	31%
Non-acne dermatological products	50	54	46	49
Non-dermatological products	25	21	24	20
Total net revenues	100%	100%	100%	100%



**Table of Contents****10. INVENTORIES**

The Company utilizes third parties to manufacture and package inventories held for sale, takes title to certain inventories once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventories consist of salable products held at the Company's warehouses, as well as raw materials and components at the manufacturers' facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company provides valuation reserves for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.

Inventories at March 31, 2005 and June 30, 2004 are as follows (amounts in thousands):

	March 31, 2005	June 30, 2004
Raw materials	\$ 6,623	\$ 8,785
Finished goods	12,794	11,105
Valuation reserve	(350)	(350)
Total inventories	\$ 19,067	\$ 19,540

**11. CONTINGENT CONVERTIBLE SENIOR NOTES**

In June 2002, the Company sold \$400.0 million aggregate principal amount of its 2.5% Contingent Convertible Notes Due 2032 (the "Old Notes") in private transactions. As discussed below, approximately \$230.8 million in principal amount of the Old Notes was exchanged for New Notes on August 14, 2003. The Old Notes bear interest at a rate of 2.5% per annum, which is payable on June 4 and December 4 of each year, beginning on December 4, 2002. The Company also agreed to pay contingent interest at a rate equal to 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2007, if the average trading price of the Old Notes reaches certain thresholds. The Old Notes will mature on June 4, 2032.

The Company may redeem some or all of the Old Notes at any time on or after June 11, 2007, at a redemption price, payable in cash, of 100% of the principal amount of the Old Notes, plus accrued and unpaid interest, including contingent interest, if any. Holders of the Old Notes may require the Company to repurchase all or a portion of their Old Notes on June 4, 2007, 2012 and 2017; and upon a change in control, as defined in the indenture governing the Old Notes, at 100% of the principal amount of the Old Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash.

The Old Notes are convertible, at the holders' option, prior to the maturity date into \_\_\_\_\_ shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after June 30, 2002, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 110% of the conversion price of the Old Notes, or \$31.96. The Old Notes are initially convertible at a conversion price of \$29.05 per share, which is equal to a conversion rate of approximately 34.4234 shares per \$1,000 principal amount of Old Notes, subject to adjustment;

if the Company has called the Old Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the Old Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the Old Notes; or

upon the occurrence of specified corporate transactions.

**Table of Contents**

The Old Notes, which are unsecured, do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants.

The Company incurred \$12.6 million of fees and other origination costs related to the issuance of the Old Notes. The Company is amortizing these costs over the five-year Put period, which runs through May 2007. The Put period runs from the date the Old Notes were issued to the date the Company may redeem some or all of the Old Notes.

On August 14, 2003, the Company exchanged approximately \$230.8 million in principal amount of its Old Notes for approximately \$283.9 million in principal amount of its 1.5% Contingent Convertible Senior Notes Due 2033 (the New Notes). Holders of Old Notes that accepted the Company's exchange offer received \$1,230 in principal amount of New Notes for each \$1,000 in principal amount of Old Notes. The terms of the New Notes are similar to the terms of the Old Notes, but have a different interest rate, conversion rate and maturity date. Holders of Old Notes that chose not to exchange continue to be subject to the terms of the Old Notes.

The New Notes bear interest at a rate of 1.5% per annum, which is payable on June 4 and December 4 of each year, beginning December 4, 2003. The Company will also pay contingent interest at a rate of 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2008, if the average trading price of the New Notes reaches certain thresholds. The New Notes mature on June 4, 2033.

The Company may redeem some or all of the New Notes at any time on or after June 11, 2008, at a redemption price, payable in cash, of 100% of the principal amount of the New Notes, plus accrued and unpaid interest, including contingent interest, if any. Holders of the New Notes may require the Company to repurchase all or a portion of their New Notes on June 4, 2008, 2013 and 2018, and upon a change in control, as defined in the indenture governing the New Notes, at 100% of the principal amount of the New Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash.

The New Notes are convertible, at the holders' option, prior to the maturity date into \_\_\_\_\_ shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after September 30, 2003, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 120% of the conversion price of the New Notes, or \$46.51. The Notes are initially convertible at a conversion price of \$38.76 per share, which is equal to a conversion rate of approximately 25.7998 shares per \$1,000 principal amount of New Notes, subject to adjustment;

if the Company has called the New Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the New Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the New Notes; or

upon the occurrence of specified corporate transactions.

The New Notes, which are unsecured, do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.





**Table of Contents**

As a result of the exchange, the outstanding principal amounts of the Old Notes and the New Notes were \$169.2 million and \$283.9 million, respectively. Both the New Notes and Old Notes are reported in aggregate on the Company's condensed consolidated balance sheets. During the quarter ended September 30, 2003, the Company recognized a loss on early extinguishment of debt totaling \$58.7 million, consisting of a \$53.1 million premium and a \$5.6 million write-off of corresponding fees incurred in connection with the issuance of the Old Notes. The Company incurred approximately \$5.1 million of fees and other origination costs related to the issuance of the New Notes. The Company is amortizing these costs over the five-year Put period, which runs through August 2008. The Put period runs from the date the New Notes were issued to the date the Company may redeem some or all of the New Notes.

During the quarters ended December 31, 2004, September 30, 2004, June 30, 2004, March 31, 2004 and December 31, 2003, the Old Notes met the criteria for the right of conversion into shares of the Company's Class A common stock. This right of conversion of the Holders of Old Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarters ended December 31, 2004, September 30, 2004, June 30, 2004, March 31, 2004 and December 31, 2003. Holders of Old Notes had this conversion right only until March 31, 2005. At the end of all future quarters, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved. During the three months ended September 30, 2004 and March 31, 2004, outstanding principal amounts of \$2,000 and \$6,000 of Old Notes, respectively, were converted into shares of the Company's Class A common stock. As of May 9, 2005, no other Old Notes had been converted.

**12. INCOME TAXES**

Income taxes have been provided for using the liability method in accordance with Statement of Financial Accounting Standard No. 109, Accounting for Income Taxes. The provision for income taxes reflects management's estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate is re-evaluated by management each quarter based on the Company's estimated tax expense for the year.

At March 31, 2005, the Company had a federal net operating loss carryforward of approximately \$67.5 million that begins expiring in varying amounts in the years 2008 through 2021 if not previously utilized. The net operating loss carryforward was acquired in connection with the Company's merger with Ascent during fiscal 2002. As a result of the merger and related ownership change for Ascent, the annual utilization of the net operating loss carryforward is limited under Internal Revenue Code Section 382. Based upon this limitation, the Company estimates that approximately \$21.0 million of the \$67.5 million net operating loss carryforward will be realized. Accordingly, a valuation reserve has been recorded for the remaining net operating loss carryforward that is not expected to be realized.

At March 31, 2005, the Company had a research and experimentation credit carryforward of approximately \$1.3 million that begins expiring in varying amounts in the years 2008 through 2024 if not previously utilized. All of the research and experimentation credit carryforward was acquired in connection with the Company's merger with Ascent during fiscal 2002 and is subject to the limitation under Internal Revenue Code Section 383. As a result of this limitation, the Company does not expect to realize any of the research and experimentation credits acquired from Ascent. Accordingly, a valuation reserve of \$1.3 million has been established for the acquired research and experimentation credits.

As a result of the limitations described above, the Company recorded a deferred tax asset valuation allowance of \$17.5 million related to the net operating loss and research and experimentation credit carryforwards acquired in the merger with Ascent. Subsequent realization of loss and credit carryforwards in excess of the amounts, which the Company estimates will be realized as of March 31, 2005 will be applied to reduce the valuation allowance and goodwill recorded in connection with the merger with Ascent.

The Company took advantage of additional tax deductions available relating to the exercise of non-qualified stock options and disqualified dispositions of incentive stock options. Accordingly, the Company recorded a \$4.6 million increase to equity with a corresponding \$4.6 million reduction to taxes payable for the

**Table of Contents**

nine months ended March 31, 2005. Quarterly adjustments for the exercise of non-qualified stock options and disqualified dispositions of incentive stock options may vary as they relate to the actions of the option holder or shareholder.

**13. STOCK TRANSACTIONS**

During September 2004, all 758,032 shares of the Company's Class B common stock were exchanged for 758,032 shares of the Company's Class A common stock. As of December 31, 2004, there were no shares of Class B common stock outstanding.

During the three months ended December 31, 2004 and September 30, 2004, Medicis purchased 2,177,286 and 1,743,800 shares of its Class A common stock in the open market at an average price of \$38.65 and \$37.76 per share, respectively. These stock purchases were made in accordance with a stock repurchase program that was approved by the Company's Board of Directors in August 2004. This program provided for the repurchase of up to \$150.0 million of Class A common stock at such times as management determined. As of December 31, 2004, the Company had repurchased a total of approximately \$150.0 million of Class A common stock pursuant to this program, all during the six months ended December 31, 2004. As the purchase limit had been reached, the plan was terminated. During the three months ended March 31, 2005 and the three and nine months ended March 31, 2004, Medicis did not purchase any of its shares of Class A common stock.

**14. DIVIDENDS DECLARED ON COMMON STOCK**

On March 16, 2005, the Company declared a cash dividend of \$0.03 per issued and outstanding share of its Class A common stock payable on April 29, 2005 to stockholders of record at the close of business on April 1, 2005. The \$1.6 million dividend was recorded as a reduction of accumulated earnings and is included in other current liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2005.

On December 14, 2004, the Company declared a cash dividend of \$0.03 per issued and outstanding share of its Class A common stock payable on January 31, 2005 to stockholders of record at the close of business on January 3, 2005. The \$1.6 million dividend was recorded as a reduction of accumulated earnings.

On September 14, 2004, the Company declared a cash dividend of \$0.03 per issued and outstanding share of its Class A common stock payable on October 29, 2004 to stockholders of record at the close of business on October 1, 2004. The \$1.7 million dividend was recorded as a reduction of accumulated earnings.

**15. COMPREHENSIVE INCOME**

Total comprehensive income includes net income and other comprehensive income, which consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments. Total comprehensive income for the three months and nine months ended March 31, 2005 was \$18.6 million and \$40.5 million, respectively. Total comprehensive income for the three months and nine months ended March 31, 2004 was \$20.7 million and \$6.0 million, respectively.

**Table of Contents****16. NET INCOME PER SHARE**

The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

	<b>Three Months Ended March 31,</b>		<b>Nine Months Ended March 31,</b>	
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
<b>BASIC</b>				
Net income	\$ 19,371	\$ 20,671	\$ 40,595	\$ 7,135
Weighted average number of common shares outstanding	54,251	56,042	55,506	55,198
Basic net income per common share	\$ 0.36	\$ 0.37	\$ 0.73	\$ 0.13
<b>DILUTED</b>				
Net income	\$ 19,371	\$ 20,671	\$ 40,595	\$ 7,135
Add:				
Tax-effected interest expense and issue costs related to Old Notes	836	836	2,511	
Tax-effected interest expense and issue costs related to New Notes	839	830	2,515	
Net income assuming dilution	\$ 21,046	\$ 22,337	\$ 45,621	\$ 7,135
Weighted average number of common shares	54,251	56,042	55,506	55,198
Effect of dilutive securities:				
Old Notes	5,823	5,823	5,823	
New Notes	7,325	7,325	7,325	
Stock options and restricted stock	2,374	3,974	2,835	3,371
Weighted average number of common shares assuming dilution	69,773	73,164	71,489	58,569
Diluted net income per common share	\$ 0.30	\$ 0.31	\$ 0.64	\$ 0.12

Diluted net income per share must be calculated using the if-converted method in accordance with EITF 04-8, Effect of Contingently Convertible Debt on Diluted Earnings per Share. Diluted net income per share is calculated by adjusting net income for tax-effected net interest and issue costs on the Old Notes and New Notes, divided by the weighted average number of common shares outstanding assuming conversion. Prior year results have been restated to conform to EITF 04-8.

The diluted net income per common share computation for the three months ended March 31, 2005 excludes approximately 2.8 million shares of stock that represented outstanding stock options whose exercise prices were greater than the average market price of the common shares during the period and were anti-dilutive.

The diluted net income per common share computation for the nine months ended March 31, 2005 and 2004 excludes approximately 2.5 million and 20,735 shares of stock that represented outstanding stock options whose exercise prices were greater than the average market price of the common shares during the period and were anti-dilutive. For the nine months ended March 31, 2004, potentially dilutive securities

## **Table of Contents**

consisted of approximately 5.8 million and 7.3 million shares of common stock, respectively, issuable upon conversion of the Old Notes and New Notes were excluded from the diluted net income per common share computation as they were anti-dilutive.

### **17. CONTINGENCIES**

The Company and certain of its subsidiaries are parties to actions and proceedings incident to their businesses, including litigation regarding its intellectual property, challenges to the enforceability or validity of its intellectual property and claims that its products infringe on the intellectual property rights of others. Although the outcome of these actions is not presently determinable, the Company believes, at the present time, that the ultimate resolution of these matters will not have a material adverse effect on its business. In the Company's opinion, based upon consultation with legal counsel, as of March 31, 2005, the ultimate outcome with respect to any of these matters, based on the information available to the Company, is either covered by insurance and/or established reserves, or in some cases rights of offset and/or indemnification, and individually or in the aggregate will not have a material adverse effect on the Company's business, financial condition or results of operations.

## **Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

### **EXECUTIVE SUMMARY**

We are a leading specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing of products in the United States for the treatment of dermatological, aesthetic and podiatric conditions. We also market products in Canada for the treatment of dermatological and aesthetic conditions. We have built our business by executing a four-part growth strategy. This strategy consists of promoting existing core brands, developing new products and important product line extensions, entering into strategic collaborations, and acquiring complementary products, technologies and businesses. We cultivate relationships of trust and confidence with the high prescribing dermatologists and podiatrists and the leading plastic surgeons in the United States.

We offer a broad range of products addressing various conditions including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). We currently offers 15 branded products. Our core brands are DYNACIN® (minocycline HCl), LOPROX® (ciclopirox), OMNICEF® (cefдинир), PLEXION® (sodium sulfacetamide/sulfur), RESTYLANE® (hyaluronic acid), TRIAZ® (benzoyl peroxide), and VANOS (fluocinonide) Cream 0.1%. For the nine months ended March 30, 2005, core brands accounted for approximately 75% of our total net revenues. All of our core brands enjoy branded market leadership in the segments in which they compete. Because of the significance of these brands to our business, we concentrate our sales and marketing efforts in promoting them to physicians in our target markets. We also sell a number of other products that are considered less critical to our business.

In March 2003, we expanded into the dermal aesthetic market through its acquisition of the exclusive United States and Canadian rights to market, distribute and commercialize the dermal restorative product lines known as RESTYLANE®, PERLANE and RESTYLANE FINE LINES from Q-Med AB, a Swedish biotechnology/medical device company and its affiliates, collectively Q-Med. RESTYLANE® has been approved by the Food and Drug Administration (the FDA) for use in the United States as a medical device for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. RESTYLANE®, PERLANE and RESTYLANE FINE LINES have been approved for use in Canada. Q-Med currently promotes these market-leading, patented non-animal stabilized hyaluronic acid brands in over 75 countries, where over 1.5 million procedures have been performed. RESTYLANE® is marketed and sold in over 75 countries outside the United States. Since 1996, dermatologists and plastic surgeons

outside the U.S. have used it to contour and restore volume to skin and temporarily eliminate wrinkles and facial folds. Additionally, in certain countries other than the United States (such as Canada), RESTYLANE® also is approved to enhance the appearance and fullness of lips.



## **Table of Contents**

Our current product lines are divided between the Dermatological and Non-dermatological fields. The Dermatological field represents products for the treatment of Acne and Acne-related dermatological conditions and Non-acne dermatological conditions. The Non-dermatological field represents products for the treatment of Asthma (until May 2004) and Urea Cycle Disorder. The Acne and Acne-related dermatological product lines include core brands DYNACIN<sup>®</sup>, PLEXION<sup>®</sup> and TRIAZ<sup>®</sup>. The Non-acne dermatological product lines include core brands LOPROX<sup>®</sup>, OMNICEF<sup>®</sup>, RESTYLANE<sup>®</sup> and VANOS<sup>™</sup>. The Non-dermatological product lines include AMMONUL<sup>®</sup>, BUPHENYL<sup>®</sup> and ORAPRED<sup>®</sup>. ORAPRED<sup>®</sup> was one of the Company's core brands until it was licensed to BioMarin in May 2004. The Non-dermatological field also includes contract revenues associated with licensing agreements.

OMNICEF<sup>®</sup> is a trademark of Fujisawa Pharmaceutical Co. Ltd. and is used under a license from Abbott Laboratories, Inc.

In addition, we have developed and obtained rights to pharmaceutical agents in various stages of development. We have a variety of products under development, ranging from new products to existing product line extensions and reformulations of existing products. Our strategy involves the rapid evaluation and formulation of new therapeutics by obtaining preclinical safety and efficacy data, when possible, followed by rapid safety and efficacy testing in humans. Over the next four years, our objective is to launch one new product annually through our research and development efforts. As a result of our increasing financial strength, we have begun adding long-term projects to our development pipeline and may add longer-term projects with inherently greater risk in the future. Historically, we have supplemented our research and development efforts by entering into research and development agreements with other pharmaceutical and biotechnology companies.

## **Key Aspects of Our Business**

We derive a majority of our prescription volume from our core prescription products. We believe that sales of our core prescription products and sales of our dermal aesthetic product, RESTYLANE<sup>®</sup>, which we began selling in the United States on January 6, 2004, will in the aggregate constitute the majority of our sales for the foreseeable future.

We have built our business by executing a four-part growth strategy. This strategy consists of promoting existing core brands, developing new products and important product line extensions, entering into strategic collaborations and acquiring complementary products, technologies and businesses.

As a result of customer buying patterns, a substantial portion of our product revenues has been recognized in the last month of each quarter. We schedule our inventory purchases to meet anticipated customer demand. As a result, relatively small delays in the receipt of manufactured products by us could result in revenues being deferred or lost. Our operating expenses are based upon anticipated sales levels, and a high percentage of our operating expenses are relatively fixed in the short term. Consequently, variations in the timing of revenue recognition could cause significant fluctuations in operating results from period to period and may result in unanticipated periodic earnings shortfalls or losses.

We estimate customer demand for our prescription products primarily through use of third party syndicated data sources which track prescriptions written by health care providers and dispensed by licensed pharmacies. These data are extrapolations from information provided only by certain pharmacies and are estimates of historical demand levels. We observe trends from these data, and, coupled with certain proprietary information, prepare demand forecasts that are the basis for purchase orders for finished and component inventory from our third party manufacturers and suppliers. Our forecasts may fail to accurately anticipate ultimate customer demand for products. Overestimates of demand may result in excessive inventory production; underestimates may result in inadequate supply of our products in channels of distribution.

We sell our products primarily to major wholesalers and retail pharmacy chains. Consistent with pharmaceutical industry patterns, approximately 80% of our revenues are derived from four major drug wholesale concerns. While we attempt to estimate inventory levels of our products at our major wholesale customers, using historical prescription information and historical purchase patterns, this process is

## **Table of Contents**

inherently imprecise. Rarely do wholesale customers provide us complete inventory levels at regional distribution centers, or within their national distribution systems. We rely wholly upon our wholesale and drug chain customers to effect the distribution allocation of our products. Based upon historically consistent purchasing patterns of our major wholesale customers, we believe our estimates of trade inventory levels of our products are reasonable. We further believe that inventories of our products among wholesale customers, taken as a whole, are similar to those of other specialty pharmaceutical companies, and that our trade practices, which periodically involve volume discounts and early payment discounts, are typical of the industry.

We periodically offer promotions to wholesale and chain drugstore customers to encourage dispensing of our products, consistent with prescriptions written by licensed health care providers. Because many of our products compete in multi-source markets, it is important for us to ensure the licensed health care providers' dispensing instructions are fulfilled with our branded products and are not substituted with a generic product or another therapeutic alternative product which may be contrary to the licensed health care providers' recommended and prescribed Medicis brand. We believe that a critical component of our brand protection program is maintenance of full product availability at drugstore and wholesale customers. We believe such availability reduces the probability of local and regional product substitutions, shortages and backorders, which could result in lost sales. We expect to continue providing favorable terms to wholesale and retail drug chain customers as may be necessary to ensure the fullest possible distribution of our branded products within the pharmaceutical chain of commerce.

We cannot control or significantly influence the purchasing patterns of our wholesale and retail drug chain customers. They are highly sophisticated customers that purchase products in a manner consistent with their industry practices and, presumably, based upon their projected demand levels. Purchases by any given customer, during any given period, may be above or below actual prescription volumes of any of our products during the same period, resulting in fluctuations of product inventory in the distribution channel.

As described in more detail below, the following significant events and transactions occurred during the nine months ended March 31, 2005 and affected our results of operations, our cash flows and our financial condition:

- definitive merger agreement with Inamed Corporation ( Inamed );
- amendments of agreements with BioMarin Pharmaceutical Inc. ( BioMarin );
- license of SubQ™ from Q-Med;
- license of proprietary peptide technology from Ansata Therapeutics, Inc., ( Ansata );
- amendment of strategic alliance with aaiPharma Inc. ( aaiPharma );
- license of product rights to Taro Pharmaceutical Industries, Inc., ( Taro );
- FDA approval of VANOS™ and AMMONUL®;
- repurchases of \$150.0 million of Class A common stock; and
- increase in amount of declared cash dividends.

### **Definitive Merger Agreement with Inamed**

On March 20, 2005, Medicis, a wholly-owned subsidiary of Medicis and Inamed entered into an Agreement and Plan of Merger. Inamed is a global healthcare company with over 25 years of experience developing, manufacturing

and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND® system for morbid obesity.

Under the terms of the Agreement and Plan of Merger, Inamed will merge with and into a subsidiary of Medicis and each share of Inamed common stock will be converted into the right to receive

## **Table of Contents**

1.4205 shares of Medicis common stock and \$30.00 in cash. The completion of the transaction is subject to several customary conditions, including the receipt of applicable approvals from Medicis and Inamed's stockholders, the absence of any material adverse effect on either party's business and the receipt of regulatory approvals. It is currently anticipated that the closing of the transaction would occur by the end of calendar 2005.

During the third quarter of fiscal 2005, the Company incurred approximately \$7.1 million of professional and other costs related to the transaction. The costs are included in other long-term assets in the accompanying condensed consolidated balance sheets. The discussions in this report relate to Medicis as a stand-alone entity and do not reflect the impact of the proposed merger with Inamed. We anticipate that we will incur significant costs related to this transaction prior to and after closing. Business integration costs related to the transaction will be expensed as incurred.

The Agreement and Plan of Merger was filed with the SEC by the Company as part of an 8-K filed on March 21, 2005.

## **Amendments of Agreements with BioMarin**

On January 12, 2005, BioMarin and the Company entered into amendments to the Securities Purchase Agreement and License Agreement entered into on May 18, 2004, a Convertible Promissory Note ( Convertible Note ) and a Settlement and Mutual Release Agreement (collectively the Agreements ). Under the terms of the Agreements, transaction payments from BioMarin to Medicis previously totaling \$175 million were reduced to \$159 million. Beginning with license payments relating to ORAPRED® to be made by BioMarin after July 2005, license payments totaling \$93 million were reduced pro rata to \$88.4 million. Consideration to be received by Medicis from BioMarin in 2009 for the option relating to the purchase of all outstanding shares of Ascent Pediatrics were reduced from \$82 million to \$70.6 million. Medicis will take full financial responsibility for contingent payments due to former Ascent Pediatric shareholders without the \$5 million offset payment that would have been paid by BioMarin to Medicis after July 1, 2005. Contingent payments are due to former Ascent Pediatric shareholders from Medicis only if revenue from Ascent Pediatric products exceeds certain thresholds. In addition, Medicis will reimburse BioMarin for actual returns, up to certain agreed-upon limits, of ORAPRED® finished goods received by BioMarin during the quarters ended December 31, 2004, March 31, 2005 and June 30, 2005.

Additionally, Medicis will make available to BioMarin a Convertible Note up to \$25 million beginning July 1, 2005 based on certain terms and conditions including a change of control provision. Money advanced under the Convertible Note is convertible into BioMarin shares at a strike price equal to the BioMarin average closing price for the 20 trading days prior to such advance. The Convertible Note matures on the option purchase date in 2009 as defined in the Securities Purchase Agreement but may be repaid by BioMarin at any time prior to the option purchase date. In conjunction with the Agreements, BioMarin and Medicis have entered into a settlement and Mutual Release Agreement to forever discharge each other from any and all claims, demands, damages, debts, liabilities, actions and causes of action relating to the transaction consummated by the parties other than certain continuing obligations in accordance with the terms of the parties' agreements.

## **License of SubQ™ from Q-Med**

On July 15, 2004, we entered into an exclusive license agreement and other ancillary documents with Q-Med to market, distribute, sell and commercialize in the United States and Canada Q-Med's product currently known as SubQ™. Q-Med has the exclusive right to manufacture SubQ™ for Medicis. SubQ™ is not approved currently for use in the United States or Canada.

Under the terms of the agreement, Medicis Aesthetics Holdings Inc., a wholly owned subsidiary of Medicis, licenses SubQ™ for approximately \$80.0 million, due as follows: approximately \$30.0 million on July 15, 2004,

which was recorded as a charge to research and development expense during the first quarter of fiscal 2005; approximately \$10.0 million upon completion of certain clinical milestones; approximately \$20.0 million upon the satisfaction of certain defined regulatory milestones; and approximately \$20.0 million upon U.S. launch of SubQ™. In addition, we incurred approximately \$0.7 million of professional

## **Table of Contents**

fees related to the completion of the agreement during the first quarter of fiscal 2005, which was included in selling, general and administrative expenses. We also will make additional milestone payments to Q-Med upon the achievement of certain commercial milestones.

SubQ™ is comprised of the same NASHA™ (non-animal stabilized hyaluronic acid) substance as RESTYLANE®, PERLANE and RESTYLANE FINE LINES™ with a larger gel particle size and is understood to have patent protection until at least 2015.

NASHA™ is a trademark of Q-Med used under license.

## **License of Proprietary Peptide Technology from Ansata**

On December 13, 2004, we entered into an exclusive development and license agreement and other ancillary agreements with Ansata. The development and license agreement grants us the exclusive, worldwide rights to Ansata's early stage, proprietary antimicrobial peptide technology. In accordance with the development and license agreement, we paid \$5.0 million upon signing of the contract and will pay approximately \$9.0 million upon the successful completion of certain developmental milestones. Should we continue with the development of this technology, we will incur additional milestone payments beyond the development and license agreement. The initial \$5.0 million payment was recorded as a charge to research and development expense during the second quarter of fiscal 2005. In addition, we incurred approximately \$0.5 million of professional fees related to the completion of the agreements, which was included in selling, general and administrative expense during the second quarter of fiscal 2005.

Ansata exploits its proprietary antimicrobial peptide technology platform to develop novel therapeutics for topical dermatologic indications. These peptides are an integral part of the body's innate immune defense system and represent a new class of anti-infective drugs capable of combating multi-drug resistant pathogens. Ansata's discovery program focuses on improving naturally occurring human antimicrobial peptides. Based on these efforts, Ansata has discovered, and is now developing, several promising molecules for the treatment of dermatologic diseases caused by infectious organisms.

Based on Ansata's proprietary discovery technology, its scientists have introduced specific and directed modifications into these naturally occurring peptides that have resulted in significant improvements in efficacy, stability and bioavailability. This focused screening effort enables the rapid identification of those peptides displaying enhanced activity, hence, shortening the time from research to clinic.

## **Amendment of Strategic Alliance with aaiPharma**

On January 28, 2005, the Company amended its strategic alliance with aaiPharma previously initiated in June 2002 for the development, commercialization and license of a dermatologic product. The consummation of the amendment has not affected the timing of the development project. The amendment allowed for the immediate transfer of the work product as defined under the agreement, as well as the product's management and development, to Medicis, and provides that aaiPharma will continue to assist Medicis with the development of the product on a fee for services basis. Medicis will have no future financial obligations to pay aaiPharma on the attainment of clinical milestones, but incurred approximately \$8.3 million as a charge to research and development expense during the third quarter of fiscal 2005, as part of the amendment and the assumption of all liabilities associated with the project.

In addition to the amendment, Medicis entered into a supply agreement with aaiPharma for the eventual manufacture of the product by aaiPharma under certain conditions. Medicis has the right to qualify an alternate manufacturing facility, and aaiPharma agreed to assist Medicis in obtaining these qualifications. Upon the approval of the alternate facility and approval of the product, Medicis will pay aaiPharma approximately \$1 million.

**License of Product Rights to Taro**

On July 27, 2004, we entered into an exclusive license and optional purchase agreement with Taro pursuant to which Taro will market, distribute and sell the LUSTRA<sup>®</sup> family of products and two



## **Table of Contents**

development stage products in the United States, Canada and Puerto Rico. The LUSTRA® family of products are topical therapies prescribed for the treatment of ultra-violet-induced skin discolorations and hyperpigmentation usually associated with the use of oral contraceptives, pregnancy, hormone replacement therapy, sun damage and superficial trauma. The license agreement was effective immediately and extends through July 1, 2007, after which Taro may purchase the product lines.

### **FDA Approval of VANOS™ and AMMONUL®**

On February 11, 2005, the FDA approved our New Drug Application ( NDA ) for VANOS™, a patented Class I corticosteroid indicated for the treatment of plaque-type psoriasis. VANOS™ is a patented corticosteroid formulation which embodies the heritage of another Medicis product, LIDEX®. The unique formulation of VANOS™ provides doctors and patients with the convenience of a new super high potency vehicle in the form of a cream for once or twice daily application. VANOS™ is patent protected until 2021.

On February 17, 2005, the FDA approved AMMONUL® as an adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. The FDA granted AMMONUL® orphan drug status with seven years of exclusivity based on long-term compassionate patient use in patients with Urea Cycle Disorder. AMMONUL® is a hospital product administered intravenously.

### **Repurchases of \$150.0 Million of Class A Common Stock**

On August 26, 2004, our Board of Directors approved a new program that authorized the repurchase of up to \$150.0 million in aggregate value of shares of our Class A common stock upon satisfaction of certain conditions. The plan was adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The plan was scheduled to terminate on the earlier of the first anniversary of the plan or at the time when the purchase limit is reached. During the three months ended December 31, 2004 and September 30, 2004, we purchased 2,177,286 and 1,743,800 shares of our Class A common stock in the open market at an average price of \$38.65 and \$37.76 per share, respectively, or approximately \$84.1 and \$65.9 million, respectively, toward the \$150.0 million of repurchases allowed by this program. As the purchase limit has been reached, the plan has terminated.

### **Increase in Amount of Declared Cash Dividends**

On September 14, 2004, we declared a cash dividend of \$0.03 per issued and outstanding share of our Class A common stock payable on October 29, 2004 to stockholders of record at the close of business on October 1, 2004. On December 14, 2004, we declared a cash dividend of \$0.03 per issued and outstanding share of our Class A common stock payable on January 31, 2005 to stockholders of record at the close of business on January 3, 2005. On March 16, 2005, we declared a cash dividend of \$0.03 per issued and outstanding shares of our Class A common stock payable on April 29, 2005 to stockholders of record at the close of business on April 1, 2005. These dividends represent a 20% increase as compared to our previous quarter-end dividends.

**Table of Contents****RESULTS OF OPERATIONS**

The following table sets forth certain data as a percentage of net revenues for the periods indicated.

	<b>THREE MONTHS ENDED MARCH 31,</b>		<b>NINE MONTHS ENDED MARCH 31,</b>	
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Net revenues	100.0%	100.0%	100.0%	100.0%
Gross profit	85.4	84.0	85.1	84.0
Operating expenses	(55.1)*	(44.7)	(62.8)***	(52.0)**
Operating income	30.3	39.3	22.3	32.0
Interest (expense) income, net	0.3	(0.4)	0.0	(0.2)
Loss on early extinguishment of debt				(27.2)
Income before income tax expense	30.6	38.9	22.3	4.6
Income tax expense	(10.2)	(13.6)	(7.6)	(1.3)
Net income	20.4%	25.3%	14.7%	3.3%

\* Included in operating expenses is \$8.3 million (8.8% of net revenues) related to a research and development collaboration with aaiPharma.

\*\* Included in operating expenses is a \$2.4 million payment (1.1% of net revenues for the nine months ended March 31, 2004, respectively) to Dow Pharmaceutical, Inc. ( Dow ) for a research and development collaboration.

\*\*\* Included in operating expenses is \$8.3 million (3.0% of net revenues) related to a research and development collaboration with aaiPharma, \$5.5 million (2.0% of net revenues) related to our exclusive development and license agreement with Ansata for proprietary technology and \$30.7 million (11.1% of net revenues) related to our exclusive license agreement with Q-Med for the development of SubQ™.

**Three Months Ended March 31, 2005 Compared to the Three Months Ended March 31, 2004****Net Revenues**

The following table sets forth the net revenues for the three months ended March 31, 2005 (the third quarter of fiscal 2005 ) and March 31, 2004 (the third quarter of fiscal 2004 ), along with the percentage of net revenues for each of our product categories (amounts in millions):

Third Quarter Fiscal 2005	Third Quarter Fiscal 2004	\$ Change	% Change
------------------------------------	------------------------------------	--------------	-------------

Net revenues	\$	95.2	\$	81.8	\$	13.4	16.3%
				Third Quarter Fiscal 2005		Third Quarter Fiscal 2004	Change
Acne and acne-related dermatological products				25.2%		25.1%	0.1%
Non-acne dermatological products				49.7%		53.9%	(4.2)%
Non-dermatological products				25.1%		21.0%	4.1%
Total net revenues				100.0%		100.0%	

Our total net revenues increased during the third quarter of fiscal 2005 primarily as a result of growth in sales of the PLEXION® and VANOS™ products and an increase in contract revenue. Core brand revenues, which includes revenues associated with RESTYLANE®, DYNACIN®, LOPROX®, OMNICEF®, PLEXION®, TRIAZ® and VANOS™, represented approximately \$69.4 million, or approximately 72.9% of net revenues, during the third quarter of fiscal 2005, a decrease of approximately 2.4%, compared to core brand revenues of approximately \$71.0 million, or approximately 86.8% of net revenues, for the third quarter of fiscal 2004. Core brand revenues for the third quarter of fiscal 2004 included net revenues of

**Table of Contents**

ORAPRED<sup>®</sup>, which was licensed to BioMarin in May 2004. Net revenues associated with our Acne and acne-related dermatological products increased slightly as a percentage of net revenues, and increased in net dollars by 16.5% primarily due to an increase in PLEXION<sup>®</sup> net revenues due to the launch of PLEXION<sup>®</sup> Cleansing Cloths during the first quarter of fiscal 2005. Net revenues associated with our Non-acne dermatological products decreased as a percentage of net revenues, but increased in net dollars by 7.3% during the third quarter of fiscal 2005, primarily due to the launch of VANOS<sup>™</sup> after approval by the FDA during the third quarter of fiscal 2005. Net revenues associated with our Non-dermatological products increased as a percentage of net revenues primarily due to the increase in contract revenues associated with the outlicensing of the ORAPRED<sup>®</sup> and LUSTRA<sup>®</sup> brands, which was greater than the revenues generated by those products for the comparable period during the third quarter of fiscal 2004. Contract revenue during the third quarter of fiscal 2005 includes fees derived from authorized generics launched on the Company's behalf.

**Gross Profit**

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to acquired products is not included in gross profit. Amortization expense related to these intangibles for the third quarter of fiscal 2004 and the third quarter of fiscal 2004 was approximately \$5.3 million and \$4.2 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the third quarter of fiscal 2005 and 2004, along with the percentage of net revenues represented by such gross profit (amounts in millions):

	Third Quarter Fiscal 2005	Third Quarter Fiscal 2004	\$ Change	% Change
Gross profit	\$ 81.3	\$ 68.7	\$ 12.6	18.3%
% of net revenues	85.4%	84.0%		

The increase in gross profit during the third quarter of fiscal 2005 as compared to the third quarter of fiscal 2004 was due to the increase in our net revenues, while the increase in gross profit as a percentage of net revenues was primarily due to the different mix of products sold during the third quarter of fiscal 2005 as compared to during the third quarter of fiscal 2004.

**Selling, General and Administrative Expenses**

The following table sets forth our selling, general and administrative expenses for the third quarter of fiscal 2005 and 2004, along with the percentage of net revenues represented by selling, general and administrative expenses (amounts in millions):

	Third Quarter Fiscal 2005	Third Quarter Fiscal 2004	\$ Change	% Change
--	------------------------------------	------------------------------------	--------------	-------------

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Selling, general and administrative	\$	31.9	\$	28.8	\$	3.1	10.9%
% of net revenues		33.5%		35.2%			

Selling, general and administrative expenses increased from the third quarter of fiscal 2004 to the third quarter of fiscal 2005 by approximately \$3.1 million, but decreased as a percentage of net revenues from the third quarter of fiscal 2004 to the third quarter of fiscal 2005 due to net revenues during the third quarter of fiscal 2005 outpacing the increase in selling, general and administrative spending. This decrease as a percentage of net revenues was primarily due to operational efficiencies which resulted in less spending.

**Table of Contents****Research and Development Expenses**

The following table sets forth our research and development expenses for the third quarter of fiscal 2005 and 2004 (amounts in millions):

	Third Quarter Fiscal 2005	Third Quarter Fiscal 2004	\$ Change	% Change
Research and development	\$ 14.5	\$ 3.1	\$ 11.4	368.7%
Charges included in research and development	\$ 8.3		\$ 8.3	100.0%

Included in research and development expenses for the third quarter of fiscal 2005 was approximately \$8.3 million related to a research and development collaboration with aaiPharma. See discussion of Amendment of Strategic Alliance with aaiPharma above. Absent this charge, research and development expenses increased \$3.1 million, or 100.2%, to \$6.2 million during the third quarter of fiscal 2005 from \$3.1 million during the third quarter of fiscal 2004. This increase was due to the timing of various research and development projects. We expect research and development expenses to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

**Depreciation and Amortization Expenses**

Depreciation and amortization expenses during the third quarter of fiscal 2005 increased \$1.3 million, or 28.6%, to \$6.1 million from \$4.7 million during the third quarter of fiscal 2004. This increase was primarily due to the amortization of expenses related to the \$19.4 million milestone payment made to Q-Med in May 2004, which is being amortized over the period from the date of payment through January 2018, and increased amortization related to certain intangible assets whose useful lives were determined to be shorter than originally estimated.

**Interest Income**

Interest income during the third quarter of fiscal 2005 increased \$0.7 million, or 29.4%, to \$3.0 million from \$2.3 million during the third quarter of fiscal 2004, primarily due to an increase in the rates achieved by our invested funds during the third quarter of fiscal 2005 as compared to the third quarter of fiscal 2004.

**Interest Expense**

Interest expense during the third quarter of fiscal 2005 increased slightly to \$2.7 million from \$2.6 million during the third quarter of fiscal 2004.

**Income Tax Expense**

The following table sets forth our income tax expense and the resulting effective tax rate stated as a percentage of pre-tax income for the third quarters of fiscal 2005 and 2004 (amounts in millions):

Third Quarter	Third Quarter
------------------	------------------

	Fiscal 2005	Fiscal 2004	\$ Change	% Change
Income tax expense	\$ 9.8	\$ 11.1	\$ (1.3)	12.0%
Effective tax rate	33.6%	35.0%		

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of tax-exempt interest, charitable contribution deductions and research and development tax credits available in the United States. Our effective tax rate may be subject to fluctuations during the fiscal year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various

**Table of Contents**

tax jurisdictions in which we operate, valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of research and development tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities. We record valuation allowances against our deferred tax assets to reduce the net carrying value to an amount that management believes is more likely than not to be realized.

Income tax expense during the third quarter of fiscal 2005 decreased 12.0%, or \$1.3 million, to \$9.8 million, from \$11.1 million in the third quarter of fiscal 2004. The decrease in income tax was primarily due to the decrease in our pre-tax income for the same period. The provision for income taxes reflects management's estimate of the effective tax rate expected to be applicable for the full fiscal year. We estimate the range of our effective tax rate for fiscal 2005 to be approximately 35%.

**Nine Months Ended March 31, 2005 Compared to the Nine Months Ended March 31, 2004****Net Revenues**

The following table sets forth the net revenues for the nine months ended March 31, 2005 (the fiscal 2005 nine months) and March 31, 2004 (the fiscal 2004 nine months), along with the percentage of net revenues for each of our product categories (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Net revenues	\$ 276.4	\$ 215.8	\$ 60.6	28.1%
		Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	Change
Acne and acne-related dermatological products		30.2%	31.6%	(1.4)%
Non-acne dermatological products		46.3%	48.8%	(2.5)%
Non-dermatological products		23.5%	19.6%	3.9%
Total net revenues		100.0%	100.0%	

Our total net revenues increased during the fiscal 2005 nine months primarily as a result of growth in sales of the DYNACIN®, PLEXION® RESTYLANE® and VANOS™ products and an increase in contract revenue. Core brand revenues, which includes revenues associated with RESTYLANE®, DYNACIN®, LOPROX®, OMNICEF®, PLEXION®, TRIAZ® and VANOS™ represented approximately \$208.0 million, or approximately 75.3% of net revenues, during the fiscal 2005 nine months, an increase of approximately 10.4%, compared to core brand revenues of approximately \$188.4 million, or approximately 87.3% of net revenues, for the fiscal 2004 nine months. Core brand revenues for the fiscal 2004 nine months included net revenues of ORAPRED®, which was licensed to BioMarin in May 2004. Net revenues associated with our Acne and acne-related dermatological products decreased as a percentage of net revenues, but increased in net dollars by 22.5% primarily due to the continued growth of DYNACIN® and an increase in PLEXION® net revenues due to the launch of PLEXION® Cleansing Cloths during the first quarter of fiscal 2005. Net revenues associated with our Non-acne dermatological products decreased as a percentage of net revenues, but increased in net dollars by 21.4% during the fiscal 2005 nine months, primarily due to the launch of



RESTYLANE® in the United States in January 2004. Net revenues associated with our Non-dermatological products increased as a percentage of net revenues primarily due to the increase in contract revenues associated with the outlicensing of the ORAPRED® and LUSTRA® brands, which was greater than the revenues generated by those products for the comparable period during the fiscal 2004 nine months. Contract revenue during the fiscal 2005 nine months includes fees derived from authorized generics launched on the Company's behalf.

### **Gross Profit**

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to acquired products is not

**Table of Contents**

included in gross profit. Amortization expense related to these intangibles for the fiscal 2005 nine months and the fiscal 2004 nine months was approximately \$14.3 million and \$10.6 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the fiscal 2005 nine months and fiscal 2004 nine months, along with the percentage of net revenues represented by such gross profit (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Gross profit	\$ 235.2	\$ 181.2	\$ 54.0	29.8%
% of net revenues	85.1%	84.0%		

The increase in gross profit during the fiscal 2005 nine months as compared to the fiscal 2004 nine months was due to the increase in our net revenues, while the increase in gross profit as a percentage of net revenues was primarily due to the different mix of products sold during the fiscal 2005 nine months as compared to during the fiscal 2004 nine months.

**Selling, General and Administrative Expenses**

The following table sets forth our selling, general and administrative expenses for the fiscal 2005 nine months and fiscal 2004 nine months, along with the percentage of net revenues represented by selling, general and administrative expenses (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Selling, general and administrative	\$ 97.7	\$ 87.9	\$ 9.8	11.1%
% of net revenues	35.3%	40.7%		

The increase in selling, general and administrative expenses from the fiscal 2004 nine months to the fiscal 2005 nine months was primarily attributable to incremental costs associated with RESTYLANE® and approximately \$1.3 million of professional fees related to research and development collaborations. The decrease in selling, general and administrative expenses as a percentage of net revenues from the fiscal 2004 nine months to the fiscal 2005 nine months was due to net revenues during the fiscal 2005 nine months outpacing the increase in selling, general and administrative spending. A pre-market approval application for RESTYLANE® was approved by the FDA on December 12, 2003, followed by the product launch and first U.S. commercial sales of RESTYLANE® on January 6, 2004. During the fiscal 2004 nine months, we incurred incremental costs associated with the establishment of a sales and marketing strategy for RESTYLANE®, prior to the commercial launch of the product.

**Research and Development Expenses**

The following table sets forth our research and development expenses for the fiscal 2005 nine months and fiscal 2004 nine months (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Research and development	\$ 59.6	\$ 12.4	\$ 47.2	381.6%
Charges included in research and development	\$ 43.3	\$ 2.4	\$ 40.9	1,686.2%

Included in research and development expenses for the fiscal 2005 nine months was approximately \$8.3 million related to the aaiPharma research and development collaboration, \$30.0 million related to the SubQ™ license agreement and \$5.0 million related to the Ansata development and license agreement. See discussion of Amendment of Strategic Alliance with aaiPharma, License of SubQ from Q-Med and License of Proprietary Peptide Technology from Ansata above. Included in research and development expenses for the fiscal 2004 nine months was a \$2.4 million milestone payment under a license and development agreement with Dow for a patented dermatological product. Absent these charges, research and

**Table of Contents**

development expenses increased \$6.3 million, or 63.9%, to \$16.3 million during the fiscal 2005 nine months from \$10.0 million during the fiscal 2004 nine months. This increase was due to the timing of various research and development projects. We expect research and development expenses to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

**Depreciation and Amortization Expenses**

Depreciation and amortization expenses during the fiscal 2005 nine months increased \$4.4 million, or 37.1%, to \$16.3 million from \$11.9 million during the fiscal 2004 nine months. This increase was primarily due to the amortization of expenses related to the \$53.3 million and \$19.4 million milestone payments made to Q-Med in December 2003 and May 2004, respectively, which are being amortized over the period from the date of payment through January 2018 and increased amortization related to certain intangible assets whose useful lives were determined to be shorter than originally estimated.

**Loss on Early Extinguishment of Debt**

On August 14, 2003, we exchanged \$230.8 million in principal amount of our Old Notes for \$283.9 million in principal amount of our New Notes. As a result of the exchange, we recognized a loss on early extinguishment of debt during the first quarter of fiscal 2004 totaling \$58.7 million, consisting of a \$53.1 million premium and a \$5.6 million write-off of corresponding fees incurred in connection with the issuance of the Old Notes.

**Interest Income**

Interest income during the fiscal 2005 nine months increased \$0.4 million, or 4.5%, to \$8.1 million from \$7.7 million during the fiscal 2004 nine months, primarily due to an increase in the rates achieved by our invested funds during the third quarter of fiscal 2005.

**Interest Expense**

Interest expense during the fiscal 2005 nine months decreased \$0.2 million, or 2.2% to \$8.0 million from \$8.2 million during the fiscal 2004 nine months. This decrease was due to the August 2003 exchange of a portion of our Old Notes, which accrue interest at 2.5% per annum, for our New Notes, which accrue interest at 1.5% per annum.

**Income Tax Expense**

The following table sets forth our income tax expense and the resulting effective tax rate stated as a percentage of pre-tax income for the fiscal 2005 nine months and fiscal 2004 nine months (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Income tax expense	\$ 21.1	\$ 2.8	\$ 18.3	645.7%
Effective tax rate	34.2%	28.4%		

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of tax-exempt interest, charitable contribution deductions and research and

development tax credits available in the United States. Our effective tax rate may be subject to fluctuations during the fiscal year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of research and development tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities. We record valuation allowances against our deferred tax assets to reduce the net carrying value to an amount that management believes is more likely than not to be realized.

**Table of Contents**

Income tax expense during the fiscal 2005 nine months increased 645.7%, or \$18.3 million, to \$21.1 million, from a tax expense of \$2.8 million in the fiscal 2004 nine months. The increase in income tax was primarily due to the increase in our pre-tax income for the same period. The provision for income taxes reflects management's estimate of the effective tax rate expected to be applicable for the full fiscal year. We estimate our effective tax rate for fiscal 2005 to be approximately 35%.

**LIQUIDITY AND CAPITAL RESOURCES****Overview**

The following table highlights selected cash flow components for the fiscal 2005 nine months and the fiscal 2004 nine months, and selected balance sheet components as of March 31, 2005 and June 30, 2004 (amounts in millions):

	Fiscal 2005 Nine Months	Fiscal 2004 Nine Months	\$ Change	% Change
Cash provided by (used in):				
Operating activities	\$ 79.4	\$ 77.4	\$ 2.0	2.5%
Investing activities	80.4	(86.8)	167.2	(192.5)%
Financing activities	(138.9)	27.9	(166.8)	(598.5)%
	Mar. 31, 2005	June 30, 2004	\$ Change	% Change
Cash, cash equivalents and short-term investments	\$ 561.3	\$ 634.0	\$ (72.7)	(11.5)%
Working capital	570.7	666.7	(96.0)	(14.4)%
2.5% contingent convertible senior notes due 2032	169.2	169.2		
1.5% contingent convertible senior notes due 2033	283.9	283.9		

**Working Capital**

Working capital as of March 31, 2005 and June 30, 2004 consisted of the following (amounts in millions):

	Mar. 31, 2005	June 30, 2004	\$ Change	% Change
Cash, cash equivalents and short-term investments	\$ 561.3	\$ 634.0	\$ (72.7)	(11.5)%
Accounts receivable, net	48.0	47.9	0.1	0.3%
Inventories, net	19.1	19.5	(0.4)	(2.4)%
Deferred tax assets, net	15.6	14.1	1.5	10.1%
Other current assets	15.5	18.3	(2.8)	(15.1)%
Total current assets	659.5	733.8	(74.3)	(10.1)%
Accounts payable	28.9	13.9	15.0	108.1%
Short-term contract obligation	27.5	17.9	9.6	53.7%
Income taxes payable	4.8	0.7	4.1	568.2%
Other current liabilities	27.6	34.6	(7.0)	(20.2)%

Total current liabilities	88.8	67.1	21.7	32.3%
Working capital	\$ 570.7	\$ 666.7	\$ (96.0)	(14.4)%

We had cash, cash equivalents and short-term investments of \$561.3 million and working capital of \$570.7 million at March 31, 2005, as compared to \$634.0 million and \$666.7 million, respectively, at June 30, 2004. The decreases were primarily due to \$150.0 million of repurchases of our Class A common stock, \$30.7 million paid in respect of the SubQ™ license agreement during the first quarter of fiscal 2005, \$5.5 million paid in respect of the Ansata development and license agreement during the second quarter of fiscal 2005 and \$8.3 million paid in respect of the research and development collaboration with aaiPharma

## **Table of Contents**

during the third quarter of fiscal 2005, partially offset by operating cash flow generated during the 2005 nine months and proceeds from the exercise of stock options received during the 2005 nine months.

Management believes existing cash and short-term investments, together with funds generated from operations, should be sufficient to meet operating requirements for the foreseeable future. Our cash and short-term investments are available for strategic investments, mergers and acquisitions, and other potential large-scale needs.

### **Net Cash Provided By Operating Activities**

Net cash provided by operating activities during the fiscal 2005 nine months increased 2.5%, or \$2.0 million, to \$79.4 million from \$77.4 million during the fiscal 2004 nine months. The \$58.7 million loss on the early extinguishment of debt recorded in the first quarter of fiscal 2004 was a non-cash charge and was added back into operating cash flows for the fiscal 2004 nine months.

### **Net Cash Provided By (Used In) Investing Activities**

Net cash provided by investing activities during the fiscal 2005 nine months was \$80.4 million, as compared to net cash used in investing activities during the fiscal 2004 nine months of \$86.8 million. The change in net cash provided by (used in) investing activities was primarily due to the net purchases or sales of our short-term investments during the respective periods. During the fiscal 2005 nine months, a significant amount of our short-term investments were sold to fund the purchase of \$150.0 million of treasury stock during the fiscal 2005 nine months. Included in net cash used in investing activities during the fiscal 2004 nine months was \$59.5 million of cash used for the purchase of product rights (including \$53.3 million paid to Q-Med upon the approval of RESTYLANE® by the FDA), and \$53.8 million of cash provided by a decrease in restricted cash.

### **Net Cash Provided By (Used In) Financing Activities**

Net cash used in financing activities during the fiscal 2005 nine months was \$138.9 million compared to net cash provided by financing activities of \$27.9 million during the fiscal 2004 nine months. The change was primarily attributable to the purchase of \$150.0 million of treasury stock during the fiscal 2005 nine months while no cash was used to purchase treasury stock during the fiscal 2004 nine months.

### **Contingent Convertible Senior Notes and Other Long-Term Commitments**

On August 14, 2003, we exchanged \$230.8 million in principal amount of our Old Notes for \$283.9 million in principal amount of our New Notes. Holders of Old Notes that accepted the Company's exchange offer received \$1,230 in principal amount of New Notes for each \$1,000 in principal amount of Old Notes. The terms of the New Notes are similar to the terms of the Old Notes, but have a different interest rate, conversion rate and maturity date. Holders of Old Notes that did not exchange will continue to be subject to the terms of the Old Notes. See Note 11 of Notes to Condensed Consolidated Financial Statements for further discussion.

The New Notes and the Old Notes are unsecured, do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of our securities and do not contain any financial covenants. The Old Notes do not contain any restrictions on the payment of dividends. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.



Except for the Old Notes, the New Notes and deferred tax liabilities, we have no long-term liabilities and had only \$87.0 million of current liabilities at March 31, 2005. Our other commitments and planned expenditures consist principally of payments we will make in connection with strategic collaborations and research and development expenditures, and we will continue to invest in sales and marketing infrastructure.

## **Table of Contents**

On March 20, 2005, Medicis entered into a Senior Secured Financing Commitment Letter with Deutsche Bank Trust Company Americas and Deutsche Securities Inc. (the Letter). Subject to the terms and conditions of the Letter, Deutsche Bank Trust Company Americas and Deutsche Securities Inc. have committed to provide \$650 million of senior secured financing to Medicis. The Letter provides that the committed financing would mature in seven years and bear interest at an adjustable rate plus LIBOR. The indebtedness would be guaranteed by the Medicis domestic subsidiaries and secured by all assets and stock owned by Medicis and its domestic subsidiaries. The Letter includes customary conditions to funding, including, without limitation, no material adverse change to the market for credit facilities similar in nature to the facility contemplated by the Letter that has had a material adverse effect on syndication, the absence of a material adverse effect on Inamed, certain ratings requirements, the accuracy of representations and warranties of the parties, and the absence of a material adverse effect on Inamed relating to the Securities and Exchange Commission's investigation of Inamed as disclosed in Inamed's Annual Report on Form 10-K for the year ended December 31, 2004. The Letter was entered into in connection with the acquisition and execution of the Agreement and Plan of Merger.

## **Repurchases of Common Stock**

In May 2003, our Board of Directors approved a new repurchase program that authorized the repurchase of up to \$75 million of our common stock. This program provided for the repurchase of Class A common stock at such times as management determined. As of June 30, 2004, we had not repurchased any shares of our Class A common stock under this program. In August 2004, our Board of Directors approved a new program that replaced the May 2003 program, which authorized the repurchase of up to \$150.0 million of our Class A common stock. During the first two quarters of fiscal 2005, we purchased a total of 3,921,086 shares of our Class A common stock in the open market at an average price of \$38.25 per share, for an aggregate purchase price of approximately \$150.0 million. As the purchase limit had been reached, the plan was terminated during the second quarter of fiscal 2005.

## **Dividends**

Since the beginning of fiscal 2004, we have paid quarterly cash dividends aggregating approximately \$10.3 million on our common stock. In addition, on March 16, 2005, we declared a cash dividend of \$0.03 per issued and outstanding share of common stock payable on April 29, 2005 to our stockholders of record at the close of business on April 1, 2005. Prior to these dividends, we had not paid a cash dividend on our common stock, and we have not adopted a dividend policy. Any future determinations to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, operating results, capital requirements and other factors that our Board of Directors deems relevant.

## **Line of Credit**

We have a revolving line of credit facility of up to \$25.0 million from Wells Fargo Bank, N.A. The facility may be drawn upon by us, at our discretion, and is collateralized by certain short-term investments. Any outstanding balance of the credit facility bears interest at a floating rate of 150 basis points in excess of the 30-day London Interbank Offered Rate and expires in November 2006. The agreement requires us to comply with certain covenants, including covenants relating to our financial condition and results of operation. We have not drawn on this credit facility.

## **Off-Balance Sheet Arrangements**

We do not have any transactions, arrangements and other relationships with unconsolidated entities that are reasonably likely to affect our liquidity or capital resources. We have no special purpose or limited purpose entities that provided off-balance sheet financing, liquidity or market or credit risk support, engage in leasing, hedging, research and development services, or other relationships that expose us to liability that is not reflected on the face of

the financial statements.

**Table of Contents**

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of the condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates related to sales allowances, chargebacks, rebates, returns and other pricing adjustments, depreciation and amortization and other contingencies and litigation. We base our estimates on historical experience and various other factors related to each circumstance. Actual results could differ from those estimates based upon future events, which could include, among other risks, changes in the regulations governing the manner in which we sell our products, changes in the health care environment and managed care consumption patterns. Our significant accounting policies are described in Note 1 to the consolidated financial statements included in our Form 10-K for the fiscal year ended June 30, 2004. We believe the following critical accounting policies affect our most significant estimates and assumptions used in the preparation of our condensed consolidated financial statements and are important in understanding our financial condition and results of operations.

**Revenue Recognition**

Revenue from product sales is recognized when the merchandise is shipped to an unrelated third party pursuant to Staff Accounting Bulletin No. 104 (SAB 104), Revenue Recognition in Financial Statements. Accordingly, revenue is recognized when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products has occurred; (iii) the selling price is both fixed and determinable; and (iv) collectibility is reasonably assured. Our customers consist primarily of large pharmaceutical wholesalers who sell directly into the retail channel. Provisions for early payment discounts, and estimates for chargebacks, managed care and Medicaid rebates, damaged product returns, exchanges for expired product are established as a reduction of product sales revenues at the time such revenues are recognized. These revenue reductions are established by us as our best estimate at the time of sale based on historical experience adjusted to reflect known changes in the factors that impact such reserves. These revenue reductions are generally reflected either as a direct reduction to accounts receivable through an allowance, or as an addition to accrued expenses if the payment is due to a party other than the wholesale or retail customer.

We enter into licensing arrangements with other parties whereby we receive contract revenue based on the terms of the agreement. The timing of revenue recognition is dependent on the level of our continuing involvement in the manufacture and delivery of licensed products. If we have continuing involvement, the revenue is deferred and recognized on a straight-line basis over the period of continuing involvement. In addition, if our licensing arrangements require no continuing involvement and payments are merely based on the passage of time, we will assess such payments for revenue recognition under the collectibility criteria of SAB 104.

We do not provide any forms of price protection to our wholesale customers and permit product returns only if the product is damaged or if it is returned within six to 12 months of expiration and the customer is committed to accepting replacement product in exchange. Our customers consist principally of financially viable wholesalers; so, revenue is recorded upon sale to the wholesaler, net of estimated provisions.

If the levels of chargebacks, managed care and Medicaid rebates, damaged product returns and exchanges for expired products fluctuate significantly and/or if our estimates do not adequately reserve for these reductions of net product revenues, our reported net product revenues could be negatively affected.

Accounts receivable are presented net of allowances related to the above provisions of approximately \$18.6 million and \$16.5 million at March 31, 2005 and June 30, 2004, respectively.

**Goodwill and Other Identifiable Intangible Assets**

We have in the past made acquisitions of products and businesses that include goodwill, license agreements, product rights, and other identifiable intangible assets. We assess the impairment of goodwill and

## **Table of Contents**

other identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Some factors we consider important which could trigger an impairment review include the following: (i) significant underperformance relative to expected historical or projected future operating results; (ii) significant changes in the manner of our use of the acquired assets or the strategy for our overall business; and (iii) significant negative industry or economic trends.

When we determine that the carrying value of goodwill and other identifiable intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment, we first will perform an assessment of the asset's recoverability based on expected undiscounted future net cash flow and, if the amount is less than the asset's value, we measure any impairment based on a projected discounted cash flow method using a discount rate determined by our management to be commensurate with the risk inherent in our current business model. In accordance with SFAS No. 142, *Goodwill and Other Intangible Assets*, we do not amortize goodwill. In lieu of amortization, we are required to perform an impairment review of goodwill on an annual basis. If we determine through the impairment process that goodwill has been impaired, we would record the impairment charge in our statement of income.

As a result of our acquisitions, we included approximately \$65.1 million and \$55.4 million of goodwill on our condensed consolidated balance sheets as of March 31, 2005 and June 30, 2004, respectively.

As a result of our acquisitions of product rights and other identifiable intangible assets, we have included approximately \$264.4 million and \$275.7 million as net intangible assets on our condensed consolidated balance sheets as of March 31, 2005 and June 30, 2004, respectively.

## **Income Taxes**

Income taxes are determined using an annual effective tax rate, which is generally less than the U.S. Federal statutory rate, primarily because of tax-exempt interest, charitable contribution deductions and research and experimentation tax credits available in the United States. Our effective tax rate may be subject to fluctuations during the fiscal year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of research and experimentation tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities. We record valuation allowances against our deferred tax assets to reduce the net carrying value to an amount that management believes is more likely than not to be realized.

Deferred income taxes are presented net of a valuation allowance of approximately \$17.5 million as of March 31, 2005 and June 30, 2004.

## **Managed Care and Medicaid Reserves**

We establish and maintain reserves for amounts payable by us to managed care organizations and state Medicaid programs for the reimbursement of portions of the retail price of prescriptions filled that are covered by these programs. The amounts estimated to be paid relating to products sold are recognized as revenue reductions and as additions to accrued expenses at the time of sale based on our best estimate of the expected prescription fill rate to these managed care and state Medicaid patients, using historical experience adjusted to reflect known changes in the factors that impact such reserves.

If the levels of managed care and Medicaid rebates fluctuate significantly and/or if our estimates do not adequately reserve for these reductions of net product revenues, our reported net product revenues could be negatively affected.

Accrued liabilities include reserves of approximately \$4.5 million and \$11.7 million at March 31, 2005 and June 30, 2004, respectively, for estimated managed care and Medicaid rebates. The decrease in the reserves from June 30, 2004 to March 31, 2005 is primarily due to the timing of payments.

**Table of Contents**

**Research and Development Costs and Accounting for Strategic Collaborations**

All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. We may continue to make up-front, non-refundable payments to third parties for new technologies and for research and development work that has been completed. These up-front payments may be expensed at the time of payment depending on the nature of the payment made.

Our policy on accounting for costs of strategic collaborations determines the timing of our recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. We are required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when we acquire certain products for which there is already an ANDA or NDA available, and there is net realizable value based on projected sales for these products, we capitalize the amount paid as an intangible asset. In addition, if we acquire product rights that are in the development phase, we expense such payments.

During the third quarter of fiscal 2005 and the fiscal 2005 nine months, we incurred and expensed approximately \$8.3 million and \$44.6 million, respectively, of up-front or development milestone payments related to research and development collaborations. Of the \$44.6 million expensed during the fiscal 2005 nine months, approximately \$1.3 million were professional fees incurred related to the completion of the collaboration agreements, and were included in selling, general and administrative expenses.

**RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

During December 2004, the FASB issued Statement No. 123R, Share-Based Payment ( SFAS No. 123R ), which requires companies to measure and recognize compensation expense for all stock-based payments at fair value. Stock-based payments include stock option grants. We grant options to purchase common stock to some of our employees and directors under various plans at prices equal to the market value of the stock on the dates the options were granted. We are required to adopt SFAS No. 123R in our first quarter of fiscal 2006, beginning July 1, 2005. Early adoption is encouraged and retroactive application of the provisions of SFAS No. 123R to the beginning of the fiscal year that includes the effective date is permitted, but not required. We have not yet adopted this pronouncement and are currently evaluating the expected impact that the adoption of SFAS No. 123R will have on our consolidated financial position, results of operations and cash flows, including the specific transition method to be utilized upon adoption. SFAS No. 123R will negatively impact our earnings.

**CAUTION REGARDING FORWARD-LOOKING STATEMENTS**

Our disclosures and analyses in this Quarterly Report on Form 10-Q include forward-looking information about our financial results and estimates, business prospects and products in research. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations or forecasts of future events, but involve substantial risks and uncertainties. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, other words and terms of similar meaning in connection with any discussion of future operations or financial performance. These include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales and marketing efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. Among the factors that could cause actual results to differ materially from our forward-looking statements are the following:



the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved;

**Table of Contents**

changes in our product mix;

manufacturing or supply interruptions;

competitive developments affecting our current growth products, such as the recent FDA approval of HYLAFORM<sup>®</sup>, HYLAFORM PLUS<sup>®</sup> and CAPTIQUE<sup>®</sup>, competitors to RESTYLANE<sup>®</sup>, a generic form of our DYNACIN<sup>®</sup> Tablets product and generic forms of our LOPROX<sup>®</sup> TS and LOPROX<sup>®</sup> Cream products;

changes in the prescribing or procedural practices of dermatologists, podiatrists and/or plastic surgeons;

the ability to successfully market both new and existing products;

difficulties or delays in manufacturing;

the ability to compete against generic and other branded products;

trends toward managed care and health care cost containment;

our ability to protect our patents and other intellectual property;

possible U.S. legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including Medicaid and Medicare and involuntary approval of prescription medicines for over-the-counter use;

legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, government investigations, and other legal proceedings;

changes in U.S. generally accepted accounting principles;

additional costs related to compliance with changing regulation of corporate governance and public financial disclosure;

any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world;

the receipt of required regulatory approvals for our merger with Inamed (including the approval of antitrust authorities necessary to complete the merger);

the ability to realize the anticipated synergies and benefits of the merger with Inamed;

the ability to timely and cost-effectively integrate Inamed's and Medicis' operations;

access to available and feasible financing (including financing for the merger with Inamed) on a timely basis;

the risks and uncertainties normally incident to the pharmaceutical and medical device industries, including product liability claims;

the risks and uncertainties associated with obtaining necessary FDA approvals, including the recent non-approval recommendation of an FDA panel relating to certain of Inamed's silicone breast implants;

growth in costs and expenses; and

the impact of acquisitions, divestitures and other significant corporate transactions, including the merger with Inamed.

## **Table of Contents**

We cannot ensure that any forward-looking statement will be accurate or realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to review any future disclosures contained in the reports that we file with the Securities and Exchange Commission. Our Annual Report on Form 10-K for the fiscal year ended June 30, 2004, includes a discussion of various factors that could cause actual results to differ materially from expected and historical results, which is incorporated herein by reference and which you should review. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list or discussion to be a complete set of all potential risks or uncertainties.

## **Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

As of March 31, 2005, there were no material changes to the information previously reported under Item 7A in our Annual Report on Form 10-K for the fiscal year ended June 30, 2004.

## **Item 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)), that are designed to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer evaluated, with the participation of other members of management, the effectiveness of our disclosure controls and procedures as of March 31, 2005 and have concluded that, as of such date our disclosure controls and procedures were effective to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms.

Although the management of our Company, including the Chief Executive Officer and the Chief Financial Officer, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

During the three months ended March 31, 2005, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **Table of Contents**

### **Sarbanes-Oxley 404 Compliance**

We continue the detailed assessment of our internal controls as called for by the Sarbanes-Oxley Act of 2002. We are simultaneously working to complete our evaluation of design phase where we have identified what may be control deficiencies in our system of internal controls, and have been performing the testing phase of our project. We expect to validate any potential control deficiencies and to assess whether or not they rise to the level of significant deficiencies or material weaknesses. We believe we are prepared to investigate any potential control deficiencies, and, where appropriate, to remediate them. Although we have made this project a top priority for the Company, there can be no assurances that all control deficiencies identified and validated will be remediated before the end of the Company's fiscal year or that the remaining unresolved control deficiencies will not rise to the level of significant deficiencies or material weaknesses.

## **Part II. Other Information**

### **Item 1. Legal Proceedings**

On November 9, 2001, prior to its merger with our Company, Ascent received notice that Triumph-Connecticut Limited Partnership and related parties ( Triumph ) had brought a civil action against it in the Business Session of the Superior Court of the Commonwealth of Massachusetts. In the action, the Triumph group claimed that the execution by Ascent of the merger agreement and the consummation of the merger without the consent of the Triumph group or the payment to the Triumph group of a specified amount breached the terms of a January 1997 securities purchase agreement, the terms of warrants issued to the Triumph group, an implied covenant of good faith and fair dealing, and certain deceptive trade laws. The Triumph group sought damages in an amount not less than \$22.1 million, plus treble damages. A hearing on cross-motions for summary judgment was held on October 16, 2003. On April 9, 2004, the court ruled on the cross-motions in Ascent's favor. Triumph's cross-motion for summary judgment was denied and Ascent's cross-motion for summary judgment was granted on all claims. The court entered its order dismissing the lawsuit on April 13, 2004. Triumph filed a notice of appeal on May 6, 2004. Both Triumph and Ascent filed appellate briefs. The Massachusetts Appeals Court held a hearing regarding Triumph's appeal on April 15, 2005. A decision may not be issued for several months. We continue to believe that the claims of the Triumph group are without merit.

On January 11, 2005, WE Pharmaceuticals, Inc. ( WE ) filed suit against the Company in the U.S. District Court for the Southern District of California ( California Action ). The complaint was served on January 25, 2005. In that action, WE alleged that Medicis breached an Asset Purchase Agreement under which Medicis acquired certain assets from WE. In the California Action, WE demanded compensatory damages, consequential damages and prejudgment interest. WE and the Company settled this matter on April 26, 2005, without any admission of liability by Medicis.

On June 21, 2004, the United States International Trade Commission ( ITC ) instituted an investigation pursuant to Section 337 of the Tariff Act of 1930, as amended, at the request of Inamed. The investigation identified Medicis Aesthetics, Inc., a wholly owned subsidiary of our company, and Q-Med as respondents in the investigation regarding Inamed's allegation of infringement of its U.S. Patent No. 4,803,075, dated February 7, 1989, by the dermal filler, RESTYLANE®. On September 16, 2004, Inamed moved to add our distributor, McKesson Corporation, as a respondent. The motion was granted by the Administrative Law Judge ( ALJ ) and affirmed by the ITC during November 2004. Inamed also filed a parallel infringement action against us and Q-Med in the U.S. District Court of the Southern District of California regarding the same patent. Inamed amended its complaint to add McKesson as a party to this action as well. This action was stayed pending the outcome of the ITC investigation. Pursuant to the Agreement and Plan of Merger (the Merger Agreement ) and related transactions entered into by Medicis, Inamed and a wholly-owned subsidiary of Medicis on March 20, 2005, Inamed filed a motion to dismiss with prejudice Inamed's

patent infringement action. In addition, Inamed consented to the dismissal of the ITC matter which has been granted and has been made final. However, if the Merger Agreement is terminated for any reason that would give rise to Medicis' obligation to pay Inamed an expense or termination fee pursuant to Section 5.10(c) of the Merger Agreement, Medicis will pay to Inamed a fee

**Table of Contents**

equal to \$16.5 million in consideration for Inamed's agreement to dismiss the litigation matters discussed above.

On October 15, 2004, BioMarin Pharmaceutical Inc. and BioMarin Pediatrics Inc. (collectively BioMarin) brought a civil action against us and Medicis Pediatrics, Inc. in the United States District Court for the Northern District of California, entitled *BioMarin Pharmaceutical Inc. and BioMarin Pediatrics Inc. v. Medicis Pharmaceutical Corp. and Medicis Pediatrics Inc.*, Civ. Action No. C 04-4374 CW (the BioMarin Action), alleging violation of Section 10(b) of the Securities Exchange Act of 1934, fraud in the inducement, negligent misrepresentation and breach of contract arising out of an Asset Purchase Agreement, License Agreement and Securities Purchase Agreement entered into by the Company and BioMarin as of May 18, 2004. BioMarin sought damages in an amount not less than \$50.0 million. BioMarin voluntarily dismissed without prejudice the BioMarin Action on October 19, 2004 in order to allow the parties the opportunity to engage in good faith settlement negotiations. On January 12, 2005, Medicis and BioMarin settled all of the claims brought by BioMarin in the BioMarin Action by entering into a Settlement and Mutual Release Agreement (the Settlement Agreement), a Convertible Promissory Note (the Note), and amendments to the original May 18, 2004 Securities Purchase Agreement and License Agreement. Under terms of the Settlement Agreement, Medicis and BioMarin discharged each other from any and all claims relating to the original transaction or the BioMarin Action other than certain continuing obligations in accordance with the terms of the parties' agreements.

Under the terms of the settlement, the transaction payments due to Medicis from BioMarin that previously totaled \$175.0 million were reduced to \$159.0 million as follows: (i) license payments relating to ORAPRED® were reduced from \$93.0 million to \$88.4 million; and (ii) BioMarin's purchase price for all outstanding shares of Ascent Pediatrics under the purchase option was reduced from \$82.0 million to \$70.6 million. In addition, Medicis will take full financial responsibility for contingent payments, if any, due to former Ascent Pediatric shareholders without the \$5.0 million offset payment that would have been paid by BioMarin to Medicis after July 1, 2005. Medicis will also reimburse BioMarin for actual returns, up to certain agreed-upon limits, of ORAPRED® finished goods received by BioMarin during the quarters ended December 31, 2004, March 31, 2005 and June 30, 2005. Finally, Medicis will make available to BioMarin the Note, under which BioMarin can draw up to \$25.0 million beginning July 1, 2005. Money advanced under the Note is convertible into BioMarin shares at a strike price equal to the average closing price for BioMarin stock during the 20 trading days prior to such advance. The Note comes due in 2009 or earlier if BioMarin undergoes a change of control.

The Company has provided documents in response to a government inquiry into the Company's marketing and promotion of LOPROX® to pediatricians. The Company is cooperating with the government but has no further information at this time regarding this matter.

We and certain of our subsidiaries are parties to other actions and proceedings incident to our businesses, including litigation regarding our intellectual property, challenges to the enforceability or validity of our intellectual property and claims that our products infringe on the intellectual property rights of others. Although the outcome of these actions is not presently determinable, we believe, at the present time, that the ultimate resolution of these matters will not have a material adverse effect on our business. In our opinion, based upon consultation with legal counsel, as of March 31, 2005, the ultimate outcome with respect to any of these matters, based upon the information available to us, is either covered by insurance and/or established reserves, or in some cases rights of offset and/or indemnification, and individually or in the aggregate will not have a material adverse effect on our business, financial condition or results of operations.



**Table of Contents****Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

The following provides information regarding our purchase, during the nine-month period ended March 31, 2005, of our Class A common stock:

		Total			Total Number of Shares Purchased as	Maximum Amount That May Yet Be
		Number	Average		Part of Publicly	Purchased
		Of Shares	Price	Total	Announced	Under the
			Paid		Plans	Plans
			per		or Programs	or
Period		Purchased	Share	Price Paid		Programs (1)
September 1	September 30, 2004	1,743,800	\$ 37.76	\$ 65,852,855	1,743,800	\$
October 1	October 31, 2004	1,573,400	\$ 38.61	\$ 60,754,849	1,573,800	\$
November 1	November 30, 2004	603,886	\$ 38.74	\$ 23,392,245	603,886	\$

We did not purchase any of our Class A common stock during July, August, or December 2004, or during the quarter ended March 31, 2005.

(1) In August 2004, our Board of Directors approved a share repurchase program that authorized the repurchase of up to \$150 million of our Class A common stock. As the purchase limit has been reached, the plan has terminated.

**Table of Contents**

**Item 6. EXHIBITS**

- Exhibit 4.1 Supplemental Indenture dated as of February 1, 2005 to Indenture dated as of August 19, 2003 between the Company and Deutsche Bank Trust Company Americas as Trustee
- Exhibit 12 Computation of Ratios of Earnings to Fixed Charges
- Exhibit 31.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- Exhibit 31.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- Exhibit 32.1 Certification by the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MEDICIS PHARMACEUTICAL CORPORATION**

Date: May 10, 2005

By: /s/ Jonah Shacknai

Jonah Shacknai  
Chairman of the Board and  
Chief Executive Officer  
(Principal Executive Officer)

Date: May 10, 2005

By: /s/ Mark A. Prygocki, Sr.

Mark A. Prygocki, Sr.  
Executive Vice President  
Chief Financial Officer, Corporate  
Secretary and Treasurer  
(Principal Financial and Accounting Officer)

**Table of Contents**

**EXHIBIT INDEX**

Exhibit 4.1	Supplemental Indenture dated as of February 1, 2005 to Indenture dated as of August 19, 2003 between the Company and Deutsche Bank Trust Company Americas as Trustee
Exhibit 12	Computation of Ratios of Earnings to Fixed Charges
Exhibit 31.1	Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification by the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002